{"gene":"GPNMB","run_date":"2026-04-28T18:06:53","timeline":{"discoveries":[{"year":1995,"finding":"GPNMB (nmb) was originally identified as a novel gene encoding a putative transmembrane glycoprotein with homology to the pMEL17 melanocyte-specific protein precursor, preferentially expressed in low-metastatic human melanoma cell lines; transfection of partial nmb cDNA into highly metastatic melanoma cells reduced subcutaneous tumor growth and metastatic potential in nude mice.","method":"Subtractive cDNA library, transfection/overexpression in vivo xenograft model","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 — original discovery with functional validation by transfection and in vivo model, single lab","pmids":["7814155"],"is_preprint":false},{"year":2007,"finding":"GPNMB (Osteoactivin) acts as a negative regulator of macrophage inflammatory responses: overexpression in RAW264.7 cells reduced LPS-induced IL-6, IL-12p40, and NO production; upon IFN-γ/LPS activation, GPNMB translocated from the Golgi apparatus (where it co-localized with coat protein beta) to peripheral vesicular compartments; DBA mice with an inactivating Gpnmb point mutation exhibited elevated proinflammatory cytokines in response to LPS.","method":"Epitope-tagged overexpression, co-localization imaging (Golgi marker), cytokine ELISA, DBA mutant mouse model","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (overexpression, subcellular localization, loss-of-function mouse model), independently replicated concept","pmids":["17475886"],"is_preprint":false},{"year":2007,"finding":"Osteoactivin/GPNMB promotes breast cancer bone metastasis; sustained GPNMB expression is required for invasion, and GPNMB overexpression elevates matrix metalloproteinase-3 (MMP-3) levels, while siRNA depletion of GPNMB reduces MMP-3 expression, identifying MMP-3 as a downstream mediator.","method":"siRNA knockdown, forced overexpression, in vivo bone metastasis model (4T1 mammary carcinoma), gene expression profiling","journal":"Molecular cancer research : MCR","confidence":"High","confidence_rationale":"Tier 2 — reciprocal gain/loss-of-function with defined molecular readout (MMP-3), in vivo validation","pmids":["17951401"],"is_preprint":false},{"year":2008,"finding":"GPNMB expression is directly transcriptionally regulated by microphthalmia transcription factor (MITF) via a conserved M-box binding site in the GPNMB promoter; EMSA identified MITF binding to this site, mutation abolished binding and transactivation, and kinetics of GPNMB induction during osteoclastogenesis paralleled known MITF targets acp5 and clcn7; GPNMB co-localized with lysosomal/endocytic marker MAC-3/LAMP-2 in mature macrophages.","method":"EMSA, reporter gene assay with promoter mutation, microarray expression profiling, immunofluorescence co-localization","journal":"Gene","confidence":"High","confidence_rationale":"Tier 1-2 — direct biochemical identification of transcription factor binding site with mutagenesis and reporter assay, replicated in multiple cell contexts","pmids":["18313864"],"is_preprint":false},{"year":2008,"finding":"Gpnmb is a MITF-dependent melanoblast-expressed gene; a conserved enhancer element (GPNMB-MCS3) containing two MITF consensus sites drives expression in melanoblasts in vivo, and deletion of the 5'-most MITF site dramatically reduces enhancer activity.","method":"Whole-genome MITF binding site annotation, luciferase reporter assay, transgenic in vivo enhancer analysis, Mitf mutant mouse expression studies","journal":"Pigment cell & melanoma research","confidence":"High","confidence_rationale":"Tier 1-2 — in vivo enhancer validation combined with mutagenesis and reporter assays","pmids":["18983539"],"is_preprint":false},{"year":2010,"finding":"ADAM10 is the sheddase responsible for proteolytic release of the GPNMB ectodomain (ECD) from breast cancer cell surfaces; siRNA-mediated knockdown of ADAM10 specifically blocked GPNMB ECD shedding, and the shed ECD promoted endothelial cell migration in vitro, identifying ectodomain shedding as a mechanism by which GPNMB promotes angiogenesis.","method":"Transient siRNA knockdown of candidate sheddases, immunoblot, ELISA, endothelial migration assay","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — systematic sheddase screen with siRNA, functional validation of shed ECD on endothelial migration","pmids":["20711474"],"is_preprint":false},{"year":2010,"finding":"GPNMB (DC-HIL) expressed on melanoma cells inhibits activation of melanoma-reactive T cells by binding syndecan-4 (SD-4) on activated T cells; siRNA knockdown of GPNMB in B16F10 melanoma markedly reduced in vivo tumor growth in immunocompetent but not immunodeficient mice, and DC-HIL-knocked-down cells showed augmented capacity to activate melanoma-reactive T cells; blocking SD-4 enhanced CD8+ T cell reactivity to melanoma antigens.","method":"siRNA knockdown, in vivo tumor growth in immunocompetent vs. immunodeficient mice, T cell activation assays, SD-4 blocking experiments","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — clean KO with defined cellular phenotype, mechanistic follow-up with receptor blocking, replicated across multiple assays","pmids":["20570888"],"is_preprint":false},{"year":2010,"finding":"GPNMB is a melanosomal protein enriched in mature (stage III-IV) melanosomes; it is released as a secreted form by ectodomain shedding from the largely Golgi-modified form, and the PKC and Ca2+ intracellular signaling pathways regulate GPNMB shedding.","method":"Subcellular fractionation, immunofluorescence, kinase inhibitor/signaling pathway pharmacology, ELISA for shed form","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 — direct organelle localization with fractionation, mechanistic pathway identification for shedding regulation","pmids":["20056711"],"is_preprint":false},{"year":2012,"finding":"GPNMB silencing by siRNA sharply reduced the total number of melanosomes in melanocytes and attenuated expression of melanosomal proteins tyrosinase, Trp1, Pmel17/gp100, and OA1, demonstrating that GPNMB is critical for melanosome formation; this effect was MITF-independent. UVB radiation upregulated GPNMB expression in melanocytes.","method":"siRNA knockdown, transmission electron microscopy (melanosome counting), Western blotting, qPCR, immunofluorescence","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — ultrastructural (TEM) and molecular validation of melanosome loss after GPNMB silencing","pmids":["22912767"],"is_preprint":false},{"year":2012,"finding":"GPNMB glycosylation is inhibited by interaction with mutant SOD1(G93A) in motor neurons, increasing their vulnerability; extracellular fragments of GPNMB secreted from activated astrocytes attenuate neurotoxicity of SOD1(G93A) in neural cells, indicating a neuroprotective paracrine role for secreted GPNMB.","method":"Co-expression studies in NSC34 cells, glycosylation assays, recombinant GPNMB treatment, neurotoxicity assays","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 3 — mechanistic findings from cell-based assays, single lab","pmids":["22891158"],"is_preprint":false},{"year":2013,"finding":"ET-1 (endothelin-1) triggers melanogenesis via the MITF-regulated GPNMB pathway: ET-1 increases MITF and GPNMB expression; siRNA knockdown of GPNMB reduces total melanosomes and melanin synthesis; siRNA knockdown of MITF suppresses GPNMB expression and ET-1-induced pigmentation, establishing GPNMB downstream of MITF in the ET-1 signaling axis.","method":"siRNA knockdown of GPNMB and MITF, melanin quantification, melanosome counting, Western blotting","journal":"BMB reports","confidence":"Medium","confidence_rationale":"Tier 2 — epistasis established by double knockdown; single lab","pmids":["23884103"],"is_preprint":false},{"year":2013,"finding":"GPNMB stimulates osteogenesis and angiogenesis via FGFR-1 signaling: recombinant GPNMB dose-dependently induced osteoblast differentiation (ALP, OCN expression) from human bone marrow stromal cells and promoted endothelial proliferation, migration, and tube formation; pretreatment with FGFR-1 siRNA or inhibitor SU5402 abolished these effects; in a rodent cranial defect model, GPNMB-delivering scaffolds increased bone and vessel formation, reversed by combined SU5402.","method":"Recombinant protein treatment, siRNA knockdown of FGFR-1, FGFR-1 inhibitor, in vitro differentiation assays, in vivo cranial defect model","journal":"Journal of cellular biochemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (siRNA + inhibitor + in vivo), consistent mechanistic conclusion","pmids":["23794283"],"is_preprint":false},{"year":2014,"finding":"In obese adipose tissue macrophages, lysosomal stress (induced by palmitate, chloroquine, or mTORC1 inhibitor Torin1) causes MITF nuclear translocation, which is absolutely required for GPNMB induction; shRNA knockdown of MITF abolished Gpnmb upregulation; in vivo, reduced mTORC1 activity in obese mouse adipose tissue macrophages coincided with increased nuclear MITF and elevated Gpnmb transcription, placing GPNMB downstream of mTORC1-MITF in lysosomal stress response.","method":"shRNA knockdown of MITF, mTORC1 inhibition, nuclear MITF localization imaging, gene expression in isolated ATMs","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 — genetic and pharmacological epistasis establishing mTORC1→MITF→GPNMB pathway, in vitro and in vivo","pmids":["24789918"],"is_preprint":false},{"year":2014,"finding":"GPNMB in LPS-activated microglia upregulates MMP-3 expression, which in turn promotes production of proinflammatory mediators (TNF-α, IL-1β, iNOS, NO); siRNA knockdown of GPNMB or MMP-3 inhibitor treatment suppressed these inflammatory mediators, establishing a GPNMB→MMP-3 axis in microglial inflammation.","method":"siRNA knockdown, MMP-3 inhibitor, ELISA for cytokines, RT-PCR and Western blotting","journal":"Journal of molecular neuroscience : MN","confidence":"Medium","confidence_rationale":"Tier 2 — epistasis via siRNA and inhibitor, single lab","pmids":["24682924"],"is_preprint":false},{"year":2014,"finding":"GPNMB neuroprotection in cerebral ischemia-reperfusion injury is associated with phosphorylation of ERK1/2 and Akt; GPNMB transgenic mice showed reduced infarct volume and increased p-ERK1/2 and p-Akt by Western blotting; recombinant GPNMB (extracellular sequence) also decreased infarction volume, indicating the neuroprotective effect is mediated by the extracellular domain.","method":"GPNMB transgenic mouse model, middle cerebral artery occlusion, Western blotting for p-ERK1/2/p-Akt, recombinant GPNMB treatment","journal":"Neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 — transgenic and recombinant protein approaches; downstream pathway by Western blot; single lab","pmids":["25010402"],"is_preprint":false},{"year":2015,"finding":"GPNMB cooperates with neuropilin-1 (NRP-1) to promote breast cancer tumor growth: GPNMB overexpression increases NRP-1 expression, potentiating VEGF signaling; NRP-1 is required for GPNMB-driven tumor growth but not metastasis. Additionally, GPNMB binds α5β1 integrin through its RGD motif, and this interaction activates Src and FAK signaling; RGD motif mutation impairs lung metastasis formation whereas both RGD motif and cytoplasmic tail are required for primary tumor growth.","method":"Forced overexpression, RNAseq, RGD motif mutagenesis, Co-IP/integrin complex pulldown, Src/FAK signaling assays, in vivo mammary tumor and metastasis models","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — domain mutagenesis, Co-IP, and in vivo validation with multiple genetic constructs","pmids":["25772243"],"is_preprint":false},{"year":2015,"finding":"GPNMB transcription in dendritic cells is regulated by MITF downstream of PI3K/Akt inhibition: IL-10 and BCR-ABL TKIs (imatinib, nilotinib) inhibit PI3K/Akt, activating GSK3β, which leads to MITF phosphorylation and nuclear translocation; a MITF activity inhibitor reduced GPNMB mRNA and protein; PI3K/Akt inhibition-induced GPNMB overexpression reduced moDC stimulatory capacity in MLRs, rescued by adding the GPNMB T cell ligand syndecan-4.","method":"Small molecule inhibitors, MITF inhibitor, mRNA/protein quantification, mixed lymphocyte reaction","journal":"Cell communication and signaling : CCS","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological epistasis establishing PI3K/Akt→GSK3β→MITF→GPNMB pathway; single lab","pmids":["25889792"],"is_preprint":false},{"year":2015,"finding":"Soluble Gpnmb ameliorated fat accumulation and fibrosis in obese liver in transgenic mice; Gpnmb concentrated in hepatic macrophages and stellate cells interacted with calnexin, which resulted in reduction of oxidative stress.","method":"Gpnmb transgenic mouse model (aP2 promoter), co-localization/interaction studies, oxidative stress assays","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 3 — Co-interaction with calnexin shown in vivo context, single lab","pmids":["26581806"],"is_preprint":false},{"year":2016,"finding":"Recombinant GPNMB promotes MSC survival, proliferation, and migration via CD44 receptor, activating downstream ERK and AKT signaling pathways; loss-of-function and rescue studies demonstrated that M2 macrophage-secreted GPNMB mediates these MSC responses via CD44.","method":"Recombinant GPNMB treatment, loss-of-function (siRNA/antibody blocking), rescue studies, Western blotting for ERK/AKT phosphorylation","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function and rescue with defined pathway readout; single lab","pmids":["26442636"],"is_preprint":false},{"year":2016,"finding":"GPNMB promotes brain glioblastoma progression via interaction with Na+/K+-ATPase α subunits, activating PI3K/Akt and MEK/ERK pathways; the interaction was identified in murine glioma models and human GBM tumors; ouabain (Na+/K+-ATPase inhibitor) suppressed GPNMB-driven glioma growth and blocked GPNMB-induced glioma cell migration.","method":"Co-immunoprecipitation, transgenic GPNMB overexpression mouse glioma model, pharmacological inhibition with ouabain, migration assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP identifying binding partner, pharmacological epistasis in vivo; single lab","pmids":["27836549"],"is_preprint":false},{"year":2016,"finding":"Recombinant GPNMB ameliorates motor neuron cell death induced by mutant TDP-43 (M337V, A315T) and serum-free stress via activation of ERK1/2 and Akt pathways; phosphorylated ERK1/2 and Akt were decreased by stress and rescued by recombinant GPNMB treatment in NSC34 motor neuron cells; GPNMB aggregates co-localize with TDP-43 aggregates in MAP-2-positive neurons in ALS spinal cord.","method":"Mutant TDP-43 plasmid transfection, recombinant GPNMB treatment, Western blotting for p-ERK1/2/p-Akt, immunohistochemistry co-localization in ALS patient tissue","journal":"Journal of neuroscience research","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic pathway identified by rescue experiment with recombinant protein; single lab","pmids":["27935101"],"is_preprint":false},{"year":2016,"finding":"GPNMB silencing via siRNA inhibits proliferation and metastasis of osteosarcoma cells (MG63, U2OS) by suppressing PI3K/Akt/mTOR signaling; IGF-1 (PI3K/AKT activator) reversed the suppressive effects, placing GPNMB upstream of PI3K/Akt/mTOR.","method":"siRNA knockdown, IGF-1 rescue, MTT proliferation and Transwell invasion assays, Western blotting for PI3K/Akt/mTOR pathway","journal":"Oncology reports","confidence":"Medium","confidence_rationale":"Tier 2 — epistasis via rescue experiment; single lab","pmids":["29620278"],"is_preprint":false},{"year":2016,"finding":"BRAF and MEK inhibitor treatment of melanoma cells induces GPNMB expression via MITF in a MITF-dependent manner (siRNA knockdown of MITF blocked treatment-induced GPNMB upregulation); GPNMB is expressed at the cell surface in MAPK inhibitor-treated cells and elevated in on-treatment biopsies from patients; combining MAPK inhibitors with CDX-011 (anti-GPNMB ADC) is more effective than MAPK inhibition alone in preclinical models.","method":"siRNA knockdown of MITF, RT-qPCR, immunoblot, FACS, serial patient biopsies, in vivo tumor models","journal":"Clinical cancer research","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis (MITF siRNA) confirmed in cell lines and patient samples, in vivo validation","pmids":["27515299"],"is_preprint":false},{"year":2017,"finding":"GPNMB expression in dendritic cells is regulated by a Takayasu arteritis risk locus (rs2069837) in IL6 through long-range chromatin looping (~520 kb); the risk allele preferentially recruits MEF2-HDAC repressive complex, suppressing GPNMB expression in monocyte-derived macrophages; HDAC inhibition reversed this suppression.","method":"EMSA, DNA affinity precipitation + mass spectrometry, luciferase reporter assay, chromosome conformation capture (3C), HDAC inhibitor treatment in primary macrophages","journal":"Annals of the rheumatic diseases","confidence":"High","confidence_rationale":"Tier 1-2 — 3C chromatin looping, biochemical identification of repressor complex by MS, functional validation with inhibitor; multiple orthogonal methods","pmids":["31315839"],"is_preprint":false},{"year":2017,"finding":"GPNMB induces BiP expression during ER stress by promoting splicing of BiP pre-mRNA; under ER stress, GPNMB relocates to the nucleus and specifically upregulates BiP mRNA through pre-mRNA splicing, acting independently of the three major ER stress transducers (IRE1, PERK, ATF6); GPNMB transgenic mice showed elevated BiP and reduced infarction after MCAO.","method":"Thapsigargin-induced ER stress, subcellular fractionation/nuclear localization imaging, mRNA splicing analysis, IRE1/PERK/ATF6 pathway inhibition, GPNMB transgenic mouse MCAO model","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — novel nuclear function identified with orthogonal pathway exclusion; single lab","pmids":["28939899"],"is_preprint":false},{"year":2017,"finding":"Gpnmb promotes M2 macrophage polarization: siRNA knockdown of Gpnmb in bone marrow-derived macrophages inhibited M2 polarization and anti-inflammatory cytokines IL-10 and TGF-β, while promoting M1 polarization and pro-inflammatory cytokines IL-1β and TNF-α; IL-4-STAT6 pathway was identified as mechanistically involved in Gpnmb-promoted M2 polarization.","method":"siRNA knockdown, macrophage polarization assays, cytokine ELISA, STAT6 pathway analysis","journal":"Cellular immunology","confidence":"Medium","confidence_rationale":"Tier 2 — siRNA epistasis with defined pathway readout; single lab","pmids":["28433199"],"is_preprint":false},{"year":2018,"finding":"GPNMB exerts anti-inflammatory effects on astrocytes via CD44: recombinant GPNMB attenuated cytokine-induced iNOS, NO, ROS, and IL-6 in astrocytes; using primary mouse astrocytes from CD44 knockout mice, the anti-inflammatory effects of GPNMB were abolished, demonstrating CD44-mediated signaling.","method":"CD44 knockout primary astrocytes, recombinant GPNMB treatment, qPCR, NO and ROS measurement, immunofluorescence","journal":"Journal of neuroinflammation","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout of receptor definitively establishes CD44-dependence; clean loss-of-function","pmids":["29519253"],"is_preprint":false},{"year":2018,"finding":"GPNMB loss-of-function (truncating alleles) causes autosomal-recessive amyloidosis cutis dyschromica in humans; GPNMB is expressed in all epidermal cells with highest staining in melanocytes, and loss of GPNMB is associated with increased amyloid deposits in the dermis, infiltrating macrophages, and loss of melanocytes, implicating GPNMB in melanosome formation, autophagy, and phagocytosis in skin.","method":"Human genetics (6 nonsense/frameshift mutations in 9 individuals), immunofluorescence of skin biopsies, histopathology","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 — human loss-of-function genetics with defined histopathological phenotype, multiple independent mutations","pmids":["29336782"],"is_preprint":false},{"year":2018,"finding":"Cell surface GPNMB on dormant breast cancer cells induces stem cell-like properties; wild-type GPNMB, but not a mutant lacking tumorigenic activity (YF mutant in hemITAM of cytoplasmic tail), induced CSC-like properties in breast epithelial cells and 3D sphere formation, demonstrating that the hemITAM tyrosine in the intracellular domain is required for GPNMB's tumorigenic function.","method":"3D sphere culture, cell surface protein isolation/flow cytometry, wild-type vs. YF-mutant GPNMB overexpression, sphere-forming frequency assay","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — structure-function mutagenesis identifying critical intracellular domain; single lab","pmids":["30224376"],"is_preprint":false},{"year":2019,"finding":"GPNMB is a direct transcriptional target of TFE3 fusion oncoproteins in translocation renal cell carcinoma; GPNMB was upregulated in a PRCC-TFE3 transgenic mouse kidney tumor model and confirmed as a direct TFE3 transcriptional target; GPNMB was also upregulated following TSC2 loss in a MiT/TFE- and mTORC1-dependent fashion in renal cell lines.","method":"PRCC-TFE3 transgenic mouse model, CRISPR-Cas9 TSC2/TFE3/TFEB knockout cell lines, IHC, transcriptional target validation","journal":"Molecular cancer research : MCR","confidence":"High","confidence_rationale":"Tier 2 — direct transcriptional target validation in transgenic model and CRISPR-edited cell lines","pmids":["31043488"],"is_preprint":false},{"year":2019,"finding":"Hepatic Gpnmb is transcriptionally upregulated when the sterol regulatory element-binding protein (SREBP) pathway is inhibited in the liver; Gpnmb is processed to a secreted form that acts as a liver-WAT cross-talk factor, stimulating lipogenesis in white adipose tissue; Gpnmb inhibition (neutralizing antibody or liver-specific knockdown) improved metabolic parameters and promoted WAT beiging.","method":"Liver-specific Gpnmb knockdown, neutralizing antibody, secreted form identification, metabolic phenotyping in diet-induced obesity model","journal":"Nature metabolism","confidence":"High","confidence_rationale":"Tier 2 — organ-specific knockdown with mechanistic pathway identification, multiple genetic and pharmacological approaches","pmids":["32694855"],"is_preprint":false},{"year":2019,"finding":"The kringle-like domain (KLD) in the extracellular domain of GPNMB is essential for its tumorigenic potential: a GPNMB(ΔKLD) deletion mutant lacked sphere and tumor formation activity and lost cell migration-promoting activity, despite retaining normal subcellular localization, Src-induced tyrosine phosphorylation, and homo-oligomerization.","method":"Domain deletion mutagenesis, 3D sphere/tumor formation assay, migration assay, subcellular localization, Western blotting","journal":"Cancer science","confidence":"Medium","confidence_rationale":"Tier 2 — domain mutagenesis with functional validation; single lab","pmids":["31127873"],"is_preprint":false},{"year":2019,"finding":"Host GPNMB interacts with porcine circovirus type 2 (PCV2) ORF5 protein (demonstrated by GST pull-down, Co-IP, and confocal microscopy) and restricts PCV2 replication; GPNMB overexpression increased Cyclin A expression and reduced S phase, while knockdown had opposite effects, suggesting GPNMB modulates cell cycle to restrict viral replication.","method":"GST pull-down, Co-IP, confocal microscopy, lentiviral overexpression/knockdown, viral replication assays, cell cycle analysis","journal":"Frontiers in microbiology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple binding assays (pulldown, Co-IP, confocal), functional replication assay; single lab","pmids":["30671053"],"is_preprint":false},{"year":2020,"finding":"Macrophage-derived soluble GPNMB activates tumor cells through the CD44 receptor to express cytokine IL-33 and its receptor IL-1RL1, triggering cancer stem cell sphere formation; recombinant IL-33 alone was sufficient to induce tumor spheroid formation with CSC features, establishing GPNMB→CD44→IL-33/IL-1RL1 paracrine axis.","method":"Gpnmb-mutant DBA/2J mouse tumor models, CD44 receptor blocking/use, recombinant IL-33 treatment, sphere formation assays","journal":"Cellular & molecular immunology","confidence":"High","confidence_rationale":"Tier 2 — in vivo mouse model, receptor identification with blocking, cytokine rescue; multiple orthogonal approaches","pmids":["32728200"],"is_preprint":false},{"year":2021,"finding":"N-glycosylated GPNMB (specifically at Asn134) binds to the C-terminus of mutated EGFR and activates EGFR independently of its ligand, promoting phosphorylation at Y845 and activating downstream STAT3 signaling; mutation of N134 glycosylation abolished GPNMB-EGFR binding and inhibited downstream signaling and cancer metastasis in NSCLC.","method":"Membrane proteomics, Co-IP (GPNMB-EGFR binding), N134 glycosylation site mutagenesis, phosphorylation assays, metastasis models","journal":"Cancer science","confidence":"High","confidence_rationale":"Tier 2 — Co-IP identifying binding partner, glycosylation site mutagenesis with defined functional consequence, in vivo metastasis validation","pmids":["33706413"],"is_preprint":false},{"year":2021,"finding":"GPNMB overexpression in an APP/PS1 Alzheimer's disease mouse model enhanced autophagy and reduced Aβ deposition via suppression of the mTOR signaling pathway; treatment with 3-MA (autophagy inhibitor) abolished the beneficial effect of GPNMB on Aβ clearance, placing GPNMB-mediated autophagy as the mechanistic route for Aβ clearance.","method":"Transgenic GPNMB overexpression in APP/PS1 mice, transmission electron microscopy for autophagy, immunofluorescence, Western blotting for mTOR/Beclin-1, pharmacological autophagy inhibition with 3-MA","journal":"Neuroscience letters","confidence":"Medium","confidence_rationale":"Tier 2 — genetic and pharmacological epistasis establishing mTOR→autophagy mechanism; single lab","pmids":["34695452"],"is_preprint":false},{"year":2021,"finding":"Gpnmb is a causal modifier of macrophage lysosome function: Gpnmb siRNA knockdown in AKR/J macrophages decreased lysosome function; CRISPR/Cas9 deletion of Gpnmb in RAW 264.7 macrophages similarly impaired lysosome function; the DBA/2J-Gpnmb+/SjJ substrain (with wild-type Gpnmb) showed recovered lysosome function compared to Gpnmb-nonsense DBA/2J, establishing Gpnmb as the causal gene at the Mlfm1 QTL.","method":"QTL mapping in AKR/J×DBA/2J intercross, siRNA knockdown, CRISPR/Cas9 knockout, lysosome function assay, congenic substrain comparison","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 — multiple independent genetic approaches (siRNA, CRISPR, QTL, congenic strain) converging on same phenotype","pmids":["33986446"],"is_preprint":false},{"year":2021,"finding":"Extracellular vesicles from GPNMB-overexpressing BMSCs activate Wnt/β-catenin signaling to stimulate osteogenic differentiation of BMSCs; DKK1 (Wnt/β-catenin inhibitor) blocked GPNMB-EV-induced osteogenesis, establishing Wnt/β-catenin as the downstream pathway.","method":"EV isolation from GPNMB-modified BMSCs, DKK1 inhibition of Wnt/β-catenin pathway, osteogenic differentiation assays, OVX rat model","journal":"Life sciences","confidence":"Medium","confidence_rationale":"Tier 2 — pathway epistasis via DKK1 inhibitor with in vivo validation; single lab","pmids":["33582177"],"is_preprint":false},{"year":2022,"finding":"GPNMB directly coimmunoprecipitates and co-localizes with α-synuclein (aSyn) in cells; in iPSC-derived neurons, loss of GPNMB resulted in loss of ability to internalize aSyn fibrils and develop aSyn pathology, linking GPNMB to aSyn fibril internalization as a mechanistic route to Parkinson's disease pathology.","method":"Co-immunoprecipitation, co-localization imaging, iPSC-derived neuron loss-of-function, aSyn fibril internalization assay","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 — Co-IP identifying aSyn as binding partner, loss-of-function in iPSC neurons with defined fibril internalization phenotype; high-profile journal with rigorous controls","pmids":["35981040"],"is_preprint":false},{"year":2022,"finding":"Macrophage-derived GPNMB activates aortic adventitial fibroblasts (AAFs) to produce extracellular matrix (ECM) via integrin αVβ1 receptor and downstream Akt and Erk signaling; Co-IP assay demonstrated GPNMB-integrin αVβ1 interaction, and siRNA or integrin inhibitor intervention confirmed this receptor mediates GPNMB's fibrotic effects on AAFs.","method":"Co-IP, siRNA knockdown, integrin inhibitor, Western blotting for Akt/Erk, in vitro AAF activation assays, GPNMB overexpression in macrophages","journal":"Translational research : the journal of laboratory and clinical medicine","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP plus genetic/pharmacological epistasis; single lab","pmids":["36566014"],"is_preprint":false},{"year":2023,"finding":"Macrophage-derived GPNMB trapped by fibrotic ECM activates resident fibroblasts; the CD44/Serpinb2 pathway is activated in fibroblasts by GPNMB, promoting pulmonary fibrosis progression; GPNMB-neutralizing antibodies or macrophage deletion alleviated fibroblast activation in fibrotic ECM from silica-instilled mice.","method":"Fibrotic ECM fractionation/proteomics, GPNMB-neutralizing antibody, macrophage depletion, gene expression analysis (Serpinb2, CD44) in fibroblasts, silica-instilled mouse model","journal":"Communications biology","confidence":"Medium","confidence_rationale":"Tier 2 — neutralizing antibody and macrophage depletion epistasis; pathway identification; single lab","pmids":["36732560"],"is_preprint":false},{"year":2023,"finding":"CCN3 activates Wnt signaling (ligand-dependent or -independent) in TNBC, which increases MITF protein, which in turn transcriptionally induces GPNMB expression; GPNMB then activates the EGFR/MAPK pathway; CCN3 knockdown reduced GPNMB expression and EGFR activity, and GPNMB overexpression rescued the anti-cancer effects of CCN3 knockdown, establishing the CCN3→Wnt→MITF→GPNMB→EGFR/MAPK axis.","method":"siRNA knockdown, overexpression rescue, transcriptome profiling, Western blotting for pathway components, TCGA dataset validation","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — rescue experiment establishing epistasis; single lab","pmids":["36737605"],"is_preprint":false},{"year":2023,"finding":"GPNMB ameliorates neuroinflammation after subarachnoid hemorrhage via the AMPK/NFκB signaling pathway: recombinant GPNMB increased p-AMPK and suppressed p-NFκB and pro-inflammatory cytokines (IL-1β, IL-6, TNF-α); AMPK inhibitor (dorsomorphin) reversed the effects of rGPNMB on p-AMPK and p-NFκB, establishing AMPK as the downstream mediator.","method":"SAH mouse model, intracerebroventricular rGPNMB injection, AMPK inhibitor epistasis, Western blotting, ELISA, BBB integrity and behavior assays","journal":"Journal of neuroimmune pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological epistasis establishing AMPK→NFκB pathway; single lab","pmids":["37919457"],"is_preprint":false},{"year":2024,"finding":"Bone-marrow-derived macrophages are the primary source of GPNMB in injured hearts after myocardial infarction (established by lineage tracing and bone-marrow transplantation); GPNMB deficiency increases mortality and cardiac rupture while viral delivery of circulating GPNMB improves heart function; GPR39 was identified as a receptor for circulating GPNMB, and GPR39 absence negated the beneficial effects of GPNMB on cardiac repair.","method":"Lineage tracing, bone-marrow transplantation, genetic loss-of-function (GPNMB KO), viral GPNMB delivery, single-cell transcriptomics, GPR39 knockout mice","journal":"Nature cardiovascular research","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic models (lineage trace, KO, viral delivery, GPR39 KO), receptor identification, in vivo validation","pmids":["39455836"],"is_preprint":false},{"year":2025,"finding":"GPNMB functions in microglial phagocytosis by wrapping engulfed pathogenic particles and presenting them to lysosomes through direct interaction with lysosomal vacuolar-type proton ATPase catalytic subunit A (ATP6V1A); genetic ablation of GPNMB impaired both phagocytic engulfment and degradation; activating ATP6V1A rescued GPNMB-deficiency-caused phagocytosis impairment.","method":"GPNMB genetic ablation, Co-immunoprecipitation (GPNMB-ATP6V1A interaction), phagocytosis assays (multiple substrates), ATP6V1A activation rescue, in vivo seizure/epilepsy model","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — Co-IP identifying novel binding partner (ATP6V1A), genetic KO with phagocytosis phenotype, rescue by pathway activation, in vivo validation","pmids":["39992792"],"is_preprint":false}],"current_model":"GPNMB is a type I transmembrane glycoprotein whose expression is transcriptionally driven by MITF downstream of mTORC1 and PI3K/Akt signaling; its ectodomain is shed by ADAM10 (regulated by PKC/Ca2+ signaling) to generate a bioactive secreted form that signals through CD44 (reducing inflammation and promoting MSC/fibroblast responses), integrin α5β1 (activating Src/FAK to drive cancer metastasis via its RGD motif), GPR39 (mediating cardiac repair), and mutated EGFR (via N134 glycosylation-dependent binding to activate STAT3); the intracellular hemITAM domain mediates tumorigenic and stem cell-promoting functions; in macrophages GPNMB acts as a negative feedback regulator of inflammation (translocating from Golgi to peripheral vesicles upon activation) and promotes M2 polarization via IL-4-STAT6, while in neurons and microglia it relocates to the nucleus during ER stress to enhance BiP pre-mRNA splicing, interacts with α-synuclein to mediate fibril internalization, and functions in lysosomal/phagocytic pathways through interaction with ATP6V1A."},"narrative":{"teleology":[{"year":1995,"claim":"The initial identification of GPNMB as a transmembrane glycoprotein enriched in low-metastatic melanoma cells, whose partial overexpression reduced metastatic potential, established the gene as a candidate suppressor of melanoma aggressiveness and linked it to pigmentation biology.","evidence":"Subtractive cDNA library from melanoma cell lines with in vivo xenograft validation","pmids":["7814155"],"confidence":"Medium","gaps":["Mechanism of metastasis suppression unknown","Partial cDNA used; full-length function not tested","Single xenograft model"]},{"year":2007,"claim":"Demonstration that GPNMB negatively regulates macrophage inflammatory responses — translocating from Golgi to peripheral vesicles upon activation — and that its natural loss-of-function (DBA/2J mice) elevates proinflammatory cytokines, established GPNMB as an intrinsic brake on innate immune activation.","evidence":"Overexpression in RAW264.7 macrophages, Golgi co-localization imaging, cytokine ELISA, DBA/2J Gpnmb-mutant mouse","pmids":["17475886"],"confidence":"High","gaps":["Receptor mediating anti-inflammatory effect not yet identified","Mechanism of vesicular translocation not resolved"]},{"year":2008,"claim":"Identification of MITF as the direct transcriptional regulator of GPNMB — binding a conserved M-box in the promoter and an enhancer element active in melanoblasts — placed GPNMB within the MiT/TFE transcriptional network governing melanocyte and osteoclast differentiation.","evidence":"EMSA, promoter mutagenesis/reporter assay, transgenic enhancer analysis, Mitf-mutant mice","pmids":["18313864","18983539"],"confidence":"High","gaps":["Whether additional MiT family members (TFE3/TFEB) regulate GPNMB in non-melanocyte contexts was unknown","Upstream signals controlling MITF occupancy at the GPNMB locus not resolved"]},{"year":2010,"claim":"Identification of ADAM10 as the sheddase releasing GPNMB's bioactive ectodomain, regulated by PKC/Ca²⁺ signaling, and the finding that GPNMB on tumor cells inhibits T cell activation via syndecan-4, established two key functional modes: paracrine signaling through ectodomain shedding and immune checkpoint activity on cancer cells.","evidence":"siRNA screen of sheddases in breast cancer cells; GPNMB knockdown in B16F10 melanoma with in vivo growth in immunocompetent vs. immunodeficient mice; syndecan-4 blocking","pmids":["20711474","20056711","20570888"],"confidence":"High","gaps":["Whether ADAM10 is the sole sheddase in all cell types not established","Structural basis of syndecan-4 interaction unknown"]},{"year":2012,"claim":"Demonstrating that GPNMB silencing sharply reduced melanosome number and melanosomal protein expression (tyrosinase, Trp1, Pmel17) in an MITF-independent manner revealed a direct structural or regulatory role for GPNMB in organelle biogenesis beyond transcriptional control.","evidence":"siRNA knockdown in melanocytes, transmission electron microscopy for melanosome counting, Western blotting","pmids":["22912767"],"confidence":"High","gaps":["Mechanism by which GPNMB maintains melanosomal proteins is not defined","Whether GPNMB acts in melanosome maturation vs. biogenesis not distinguished"]},{"year":2014,"claim":"Placing GPNMB downstream of mTORC1 inhibition → MITF nuclear translocation in macrophages during lysosomal stress connected GPNMB induction to the cellular stress-sensing apparatus and explained its upregulation in obese adipose tissue macrophages.","evidence":"shRNA MITF knockdown, mTORC1 inhibition with Torin1/palmitate, nuclear MITF imaging, in vivo obese mouse adipose tissue macrophage isolation","pmids":["24789918"],"confidence":"High","gaps":["Whether mTORC1-independent signals also regulate GPNMB in macrophages not resolved","Direct lysosomal stress sensor upstream of mTORC1 not identified"]},{"year":2015,"claim":"Structure–function dissection showed that GPNMB's RGD motif mediates integrin α5β1 binding to activate Src/FAK signaling for lung metastasis, while both RGD and the cytoplasmic tail are required for primary tumor growth; separately, PI3K/Akt inhibition→GSK3β→MITF was identified as an alternative pathway activating GPNMB transcription in dendritic cells.","evidence":"RGD motif mutagenesis, Co-IP of integrin complex, Src/FAK signaling assays, in vivo metastasis model; pharmacological epistasis in dendritic cells","pmids":["25772243","25889792"],"confidence":"High","gaps":["Whether integrin binding and syndecan-4 binding are independent or cooperative not resolved","Role of cytoplasmic tail hemITAM in integrin-mediated signaling not dissected"]},{"year":2017,"claim":"Discovery that GPNMB relocates to the nucleus during ER stress to promote BiP pre-mRNA splicing — independently of IRE1, PERK, and ATF6 — revealed an unexpected non-canonical function as a nuclear RNA-processing factor in the stress response.","evidence":"Thapsigargin-induced ER stress, nuclear fractionation, mRNA splicing analysis, pathway inhibitor exclusion, GPNMB transgenic mouse MCAO model","pmids":["28939899"],"confidence":"Medium","gaps":["Mechanism of nuclear import unknown","RNA-binding or spliceosome interaction partners not identified","Not independently replicated"]},{"year":2018,"claim":"Genetic proof from CD44-knockout astrocytes that GPNMB's anti-inflammatory signaling requires CD44, and human genetic evidence that GPNMB loss-of-function truncating mutations cause autosomal-recessive amyloidosis cutis dyschromica, together validated CD44 as a bona fide GPNMB receptor and established GPNMB's non-redundant physiological role in skin homeostasis.","evidence":"CD44-KO primary astrocyte assays with recombinant GPNMB; six independent GPNMB truncating alleles in nine ACD patients with histopathological characterization","pmids":["29519253","29336782"],"confidence":"High","gaps":["Whether CD44 mediates GPNMB signaling in all anti-inflammatory contexts not established","Molecular link between GPNMB loss and amyloid deposition not mechanistically defined"]},{"year":2019,"claim":"Identification of TFE3 fusion oncoproteins as direct transcriptional activators of GPNMB (paralleling MITF), and demonstration that the kringle-like domain (KLD) in the ectodomain is essential for tumorigenic sphere formation, refined both the transcriptional regulation and the domain architecture required for GPNMB's oncogenic functions.","evidence":"PRCC-TFE3 transgenic mouse, CRISPR TSC2/TFE3/TFEB KO cell lines; KLD deletion mutagenesis with sphere/tumor assays","pmids":["31043488","31127873"],"confidence":"High","gaps":["KLD binding partner not identified","Whether TFE3 and MITF bind the same or distinct GPNMB regulatory elements not resolved"]},{"year":2021,"claim":"Convergent genetic approaches (siRNA, CRISPR KO, QTL mapping, congenic strains) established GPNMB as a causal modifier of macrophage lysosome function and the gene underlying the Mlfm1 QTL, directly linking GPNMB to lysosomal competence beyond transcriptional correlation.","evidence":"AKR/J×DBA/2J intercross QTL, CRISPR Gpnmb KO in RAW264.7, siRNA, DBA/2J-Gpnmb+/SjJ congenic comparison","pmids":["33986446"],"confidence":"High","gaps":["Molecular mechanism by which GPNMB enhances lysosome function not identified at this stage","Whether GPNMB acts on lysosome biogenesis vs. acidification vs. substrate delivery unclear"]},{"year":2022,"claim":"Co-immunoprecipitation of GPNMB with α-synuclein and the finding that GPNMB loss in iPSC-derived neurons abolishes α-synuclein fibril internalization established GPNMB as a receptor/co-receptor for pathological α-synuclein uptake, directly implicating it in Parkinson's disease pathogenesis.","evidence":"Co-IP, co-localization, iPSC-derived neuron GPNMB loss-of-function, α-synuclein fibril internalization assay","pmids":["35981040"],"confidence":"High","gaps":["Whether GPNMB-mediated fibril internalization is protective or pathogenic in vivo not resolved","Co-receptor or downstream signaling upon fibril binding not identified"]},{"year":2024,"claim":"Identification of GPR39 as a receptor for circulating GPNMB — with GPR39 knockout negating GPNMB's cardioprotective effects after myocardial infarction — added a new receptor-signaling axis and demonstrated that bone-marrow-derived macrophages are the primary source of GPNMB in injured hearts.","evidence":"Lineage tracing, bone-marrow transplantation, GPNMB KO, viral GPNMB delivery, GPR39 KO mice, single-cell transcriptomics","pmids":["39455836"],"confidence":"High","gaps":["GPR39 downstream signaling pathway in cardiomyocytes not fully characterized","Whether GPR39 mediates GPNMB signaling in non-cardiac tissues not known"]},{"year":2025,"claim":"The discovery that GPNMB wraps phagocytosed particles and delivers them to lysosomes via direct interaction with the V-ATPase subunit ATP6V1A — with ATP6V1A activation rescuing GPNMB-deficiency phenotypes — provided the first mechanistic link between GPNMB's lysosomal and phagocytic functions.","evidence":"Co-IP of GPNMB–ATP6V1A, GPNMB genetic ablation, multi-substrate phagocytosis assays, ATP6V1A activation rescue, in vivo seizure model","pmids":["39992792"],"confidence":"High","gaps":["Structural basis of GPNMB–ATP6V1A interaction not resolved","Whether this mechanism operates in non-microglial phagocytes not tested"]},{"year":null,"claim":"Key unresolved questions include: how GPNMB's multiple receptor interactions (CD44, integrins, GPR39, EGFR, syndecan-4) are coordinated across tissues; the structural basis and functional consequences of GPNMB's nuclear translocation and RNA-splicing activity; and whether GPNMB-mediated α-synuclein fibril internalization is net protective or pathogenic in neurodegeneration in vivo.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural model of full-length GPNMB or its receptor complexes","In vivo consequence of GPNMB-mediated α-synuclein uptake for disease progression unknown","Nuclear RNA-processing mechanism not independently replicated"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[6,15,39]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[5,18,26,33,43]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[1,25,36,44]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[6,15,22,28]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[1,7]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[3,36,44]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[1,7]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[5,9,18,30,43]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[24]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[1,6,25,26,42]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[15,18,19,34,41,43]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[35,36]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[2,22,34]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[8,10,11]}],"complexes":[],"partners":["MITF","ADAM10","CD44","ATP6V1A","GPR39","SNCA","ITGA5"],"other_free_text":[]},"mechanistic_narrative":"GPNMB is a heavily glycosylated type I transmembrane protein that functions as a multifunctional regulator of inflammation, melanosome biogenesis, lysosomal activity, and tissue repair, with context-dependent roles in cancer progression and neurodegeneration. Transcriptionally controlled by MITF and related MiT/TFE family members downstream of mTORC1 and PI3K/Akt signaling [PMID:18313864, PMID:24789918, PMID:25889792, PMID:31043488], GPNMB undergoes ADAM10-mediated ectodomain shedding regulated by PKC/Ca²⁺ to generate a soluble form that signals through CD44 (suppressing inflammation in macrophages and astrocytes and activating mesenchymal stromal cells), integrin α5β1/αVβ1 (driving Src/FAK-dependent cancer metastasis via its RGD motif), GPR39 (mediating cardiac repair after myocardial infarction), and glycosylation-dependent binding to mutant EGFR (activating STAT3 in NSCLC) [PMID:20711474, PMID:29519253, PMID:25772243, PMID:39455836, PMID:33706413]. Intracellularly, GPNMB is essential for melanosome formation, promotes microglial phagocytosis by wrapping engulfed particles and delivering them to lysosomes through direct interaction with ATP6V1A, mediates α-synuclein fibril internalization in neurons, and relocates to the nucleus under ER stress to enhance BiP pre-mRNA splicing independently of canonical UPR transducers [PMID:22912767, PMID:39992792, PMID:35981040, PMID:28939899]. Loss-of-function mutations in GPNMB cause autosomal-recessive amyloidosis cutis dyschromica in humans, characterized by dermal amyloid deposits, melanocyte loss, and macrophage infiltration [PMID:29336782]."},"prefetch_data":{"uniprot":{"accession":"Q14956","full_name":"Transmembrane glycoprotein NMB","aliases":["Hematopoietic growth factor inducible neurokinin-1 type"],"length_aa":572,"mass_kda":63.9,"function":"Could be a melanogenic enzyme","subcellular_location":"Cell membrane; Melanosome membrane; Early endosome membrane","url":"https://www.uniprot.org/uniprotkb/Q14956/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GPNMB","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GPNMB","total_profiled":1310},"omim":[{"mim_id":"617920","title":"AMYLOIDOSIS, PRIMARY LOCALIZED CUTANEOUS, 3; PLCA3","url":"https://www.omim.org/entry/617920"},{"mim_id":"604368","title":"GLYCOPROTEIN NMB; GPNMB","url":"https://www.omim.org/entry/604368"},{"mim_id":"600510","title":"OCULAR PIGMENT DISPERSION WITH OR WITHOUT GLAUCOMA; OPDG","url":"https://www.omim.org/entry/600510"},{"mim_id":"182889","title":"ZONA PELLUCIDA GLYCOPROTEIN 3; ZP3","url":"https://www.omim.org/entry/182889"},{"mim_id":"105250","title":"AMYLOIDOSIS, PRIMARY LOCALIZED CUTANEOUS, 1; PLCA1","url":"https://www.omim.org/entry/105250"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"skin 1","ntpm":548.1}],"url":"https://www.proteinatlas.org/search/GPNMB"},"hgnc":{"alias_symbol":["NMB","HGFIN"],"prev_symbol":[]},"alphafold":{"accession":"Q14956","domains":[{"cath_id":"2.60.40.1930","chopping":"17-123_130-137_156-234","consensus_level":"high","plddt":85.794,"start":17,"end":234},{"cath_id":"2.60.40.10","chopping":"239-324_370-385","consensus_level":"high","plddt":94.1841,"start":239,"end":385},{"cath_id":"2.60.40.10","chopping":"388-486","consensus_level":"high","plddt":89.8399,"start":388,"end":486}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14956","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q14956-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q14956-F1-predicted_aligned_error_v6.png","plddt_mean":76.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GPNMB","jax_strain_url":"https://www.jax.org/strain/search?query=GPNMB"},"sequence":{"accession":"Q14956","fasta_url":"https://rest.uniprot.org/uniprotkb/Q14956.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q14956/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14956"}},"corpus_meta":[{"pmid":"17475886","id":"PMC_17475886","title":"Gpnmb is induced in macrophages by IFN-gamma and lipopolysaccharide and acts as a feedback regulator of proinflammatory responses.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17475886","citation_count":193,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20711474","id":"PMC_20711474","title":"ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20711474","citation_count":175,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25847941","id":"PMC_25847941","title":"EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.","date":"2015","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25847941","citation_count":146,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29519253","id":"PMC_29519253","title":"The glycoprotein GPNMB attenuates astrocyte inflammatory responses through the CD44 receptor.","date":"2018","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/29519253","citation_count":136,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35981040","id":"PMC_35981040","title":"GPNMB confers risk for Parkinson's disease through interaction with α-synuclein.","date":"2022","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/35981040","citation_count":118,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22891158","id":"PMC_22891158","title":"The potential of GPNMB as novel neuroprotective factor in amyotrophic lateral sclerosis.","date":"2012","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/22891158","citation_count":112,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32728200","id":"PMC_32728200","title":"The soluble glycoprotein NMB (GPNMB) produced by macrophages induces cancer stemness and metastasis via CD44 and IL-33.","date":"2020","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32728200","citation_count":105,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28433199","id":"PMC_28433199","title":"Glycoprotein non-metastatic melanoma protein b (Gpnmb) is highly expressed in macrophages of acute injured kidney and promotes M2 macrophages polarization.","date":"2017","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28433199","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35072947","id":"PMC_35072947","title":"GPNMB expression identifies TSC1/2/mTOR-associated and MiT family translocation-driven renal neoplasms.","date":"2022","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/35072947","citation_count":90,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29097143","id":"PMC_29097143","title":"Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB) and Cancer: A Novel Potential Therapeutic Target.","date":"2017","source":"Steroids","url":"https://pubmed.ncbi.nlm.nih.gov/29097143","citation_count":89,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32694855","id":"PMC_32694855","title":"Gpnmb secreted from liver promotes lipogenesis in white adipose tissue and aggravates obesity and insulin resistance.","date":"2019","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/32694855","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18313864","id":"PMC_18313864","title":"Microphthalmia transcription factor regulates the expression of the novel osteoclast factor GPNMB.","date":"2008","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/18313864","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26442636","id":"PMC_26442636","title":"Macrophage-Associated Osteoactivin/GPNMB Mediates Mesenchymal Stem Cell Survival, Proliferation, and Migration Via a CD44-Dependent Mechanism.","date":"2016","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26442636","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28546082","id":"PMC_28546082","title":"Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer.","date":"2017","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/28546082","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31043488","id":"PMC_31043488","title":"TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease.","date":"2019","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/31043488","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26581806","id":"PMC_26581806","title":"Beneficial impact of Gpnmb and its significance as a biomarker in nonalcoholic steatohepatitis.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26581806","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36054938","id":"PMC_36054938","title":"Integrated single-cell transcriptomic analyses reveal that GPNMB-high macrophages promote PN-MES transition and impede T cell activation in GBM.","date":"2022","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/36054938","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20570888","id":"PMC_20570888","title":"DC-HIL/glycoprotein Nmb promotes growth of melanoma in mice by inhibiting the activation of tumor-reactive T cells.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20570888","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25772243","id":"PMC_25772243","title":"GPNMB cooperates with neuropilin-1 to promote mammary tumor growth and engages integrin α5β1 for efficient breast cancer metastasis.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25772243","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18983539","id":"PMC_18983539","title":"Gpnmb is a melanoblast-expressed, MITF-dependent gene.","date":"2008","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/18983539","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28391543","id":"PMC_28391543","title":"Increased brain expression of GPNMB is associated with genome wide significant risk for Parkinson's disease on chromosome 7p15.3.","date":"2017","source":"Neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/28391543","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24789918","id":"PMC_24789918","title":"Lysosomal stress in obese adipose tissue macrophages contributes to MITF-dependent Gpnmb induction.","date":"2014","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/24789918","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25010402","id":"PMC_25010402","title":"Glycoprotein nonmetastatic melanoma protein B (GPNMB) as a novel neuroprotective factor in cerebral ischemia-reperfusion injury.","date":"2014","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25010402","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23794283","id":"PMC_23794283","title":"GPNMB enhances bone regeneration by promoting angiogenesis and osteogenesis: potential role for tissue engineering bone.","date":"2013","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23794283","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30690710","id":"PMC_30690710","title":"A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.","date":"2019","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30690710","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36050467","id":"PMC_36050467","title":"GPNMB: a potent inducer of immunosuppression in cancer.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/36050467","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28003098","id":"PMC_28003098","title":"Validating glycoprotein non-metastatic melanoma B (gpNMB, osteoactivin), a new biomarker of Gaucher disease.","date":"2016","source":"Blood cells, molecules & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/28003098","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25889792","id":"PMC_25889792","title":"The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells.","date":"2015","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/25889792","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19833906","id":"PMC_19833906","title":"Upregulation of monocyte/macrophage HGFIN (Gpnmb/Osteoactivin) expression in end-stage renal disease.","date":"2009","source":"Clinical journal of the American Society of Nephrology : CJASN","url":"https://pubmed.ncbi.nlm.nih.gov/19833906","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26305408","id":"PMC_26305408","title":"Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma.","date":"2015","source":"Pediatric blood & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26305408","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30224376","id":"PMC_30224376","title":"Glycoprotein nmb Is Exposed on the Surface of Dormant Breast Cancer Cells and Induces Stem Cell-like Properties.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30224376","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16909223","id":"PMC_16909223","title":"Selective in vitro targeting of GRP and NMB receptors in human tumours with the new bombesin tracer 177Lu-AMBA.","date":"2006","source":"European journal of nuclear medicine and molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/16909223","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25899717","id":"PMC_25899717","title":"Transgenic Expression of Osteoactivin/gpnmb Enhances Bone Formation In Vivo and Osteoprogenitor Differentiation Ex Vivo.","date":"2016","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25899717","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29336782","id":"PMC_29336782","title":"Loss of GPNMB Causes Autosomal-Recessive Amyloidosis Cutis Dyschromica in Humans.","date":"2018","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29336782","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27515299","id":"PMC_27515299","title":"MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.","date":"2016","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/27515299","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35289033","id":"PMC_35289033","title":"Tumor endothelial cell-induced CD8+ T-cell exhaustion via GPNMB in hepatocellular carcinoma.","date":"2022","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/35289033","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1423886","id":"PMC_1423886","title":"Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific carcinogen, by rabbit nasal microsomes and cytochrome P450s NMa and NMb.","date":"1992","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/1423886","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33582177","id":"PMC_33582177","title":"Extracellular vesicles from GPNMB-modified bone marrow mesenchymal stem cells attenuate bone loss in an ovariectomized rat model.","date":"2021","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33582177","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31218162","id":"PMC_31218162","title":"Microglia express GPNMB in the brains of Alzheimer's disease and Nasu-Hakola disease.","date":"2019","source":"Intractable & rare diseases research","url":"https://pubmed.ncbi.nlm.nih.gov/31218162","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19463875","id":"PMC_19463875","title":"Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.","date":"2009","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/19463875","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22912767","id":"PMC_22912767","title":"Silencing of GPNMB by siRNA inhibits the formation of melanosomes in melanocytes in a MITF-independent fashion.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22912767","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8163469","id":"PMC_8163469","title":"Desensitization of neuromedin B receptors (NMB-R) on native and NMB-R-transfected cells involves down-regulation and internalization.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8163469","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26883195","id":"PMC_26883195","title":"Osteoactivin (GPNMB) ectodomain protein promotes growth and invasive behavior of human lung cancer cells.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26883195","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28856541","id":"PMC_28856541","title":"Glycoprotein NMB: an Emerging Role in Neurodegenerative Disease.","date":"2017","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/28856541","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34695452","id":"PMC_34695452","title":"GPNMB mitigates Alzheimer's disease and enhances autophagy via suppressing the mTOR signal.","date":"2021","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/34695452","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29620278","id":"PMC_29620278","title":"GPNMB silencing suppresses the proliferation and metastasis of osteosarcoma cells by blocking the PI3K/Akt/mTOR signaling pathway.","date":"2018","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/29620278","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37661807","id":"PMC_37661807","title":"Positive GPNMB Immunostaining Differentiates Renal Cell Carcinoma With Fibromyomatous Stroma Associated With TSC1/2/MTOR Alterations From Others.","date":"2023","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/37661807","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32436108","id":"PMC_32436108","title":"Transgenic Overexpression of GPNMB Protects Against MPTP-Induced Neurodegeneration.","date":"2020","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/32436108","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36732560","id":"PMC_36732560","title":"Macrophage-derived GPNMB trapped by fibrotic extracellular matrix promotes pulmonary fibrosis.","date":"2023","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/36732560","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27935101","id":"PMC_27935101","title":"GPNMB ameliorates mutant TDP-43-induced motor neuron cell death.","date":"2016","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/27935101","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23884103","id":"PMC_23884103","title":"Endothelin-1 enhances the melanogenesis via MITF-GPNMB pathway.","date":"2013","source":"BMB reports","url":"https://pubmed.ncbi.nlm.nih.gov/23884103","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24682924","id":"PMC_24682924","title":"Induction of matrix metalloproteinase-3 (MMP-3) expression in the microglia by lipopolysaccharide (LPS) via upregulation of glycoprotein nonmetastatic melanoma B (GPNMB) expression.","date":"2014","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/24682924","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31347172","id":"PMC_31347172","title":"CSE1L silence inhibits the growth and metastasis in gastric cancer by repressing GPNMB via positively regulating transcription factor MITF.","date":"2019","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31347172","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17845721","id":"PMC_17845721","title":"Role of human HGFIN/nmb in breast cancer.","date":"2007","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/17845721","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21203347","id":"PMC_21203347","title":"C57BL/6J, DBA/2J, and DBA/2J.Gpnmb mice have different visual signal processing in the inner retina.","date":"2010","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/21203347","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39509324","id":"PMC_39509324","title":"Gpnmb and Spp1 mark a conserved macrophage injury response masking fibrosis-specific programming in the lung.","date":"2024","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/39509324","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28500250","id":"PMC_28500250","title":"Characterization of NMB, GRP and their receptors (BRS3, NMBR and GRPR) in chickens.","date":"2017","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/28500250","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34608215","id":"PMC_34608215","title":"Anti-inflammatory role of Gpnmb in adipose tissue of mice.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34608215","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12231437","id":"PMC_12231437","title":"Restraint stress impaired maternal behavior in female mice lacking the neuromedin B receptor (NMB-R) gene.","date":"2002","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/12231437","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1282662","id":"PMC_1282662","title":"Cytochromes P450 NMa, NMb (2G1), and LM4 (1A2) are differentially expressed during development in rabbit olfactory mucosa and liver.","date":"1992","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/1282662","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31822499","id":"PMC_31822499","title":"DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/31822499","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31315839","id":"PMC_31315839","title":"Takayasu arteritis risk locus in IL6 represses the anti-inflammatory gene GPNMB through chromatin looping and recruiting MEF2-HDAC complex.","date":"2019","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/31315839","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21389974","id":"PMC_21389974","title":"Hematopoietic growth factor inducible neurokinin-1 (Gpnmb/Osteoactivin) is a biomarker of progressive renal injury across species.","date":"2011","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/21389974","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36737605","id":"PMC_36737605","title":"CCN3/NOV promotes metastasis and tumor progression via GPNMB-induced EGFR activation in triple-negative breast cancer.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36737605","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20824708","id":"PMC_20824708","title":"Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas.","date":"2010","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20824708","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34919054","id":"PMC_34919054","title":"BNP facilitates NMB-encoded histaminergic itch via NPRC-NMBR crosstalk.","date":"2021","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/34919054","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8985785","id":"PMC_8985785","title":"Alanine scan and N-methyl amide derivatives of Ac-bombesin[7-14]. Development of a proposed binding conformation at the neuromedin B (NMB) and gastrin releasing peptide (GRP) receptors.","date":"1996","source":"International journal of peptide and protein research","url":"https://pubmed.ncbi.nlm.nih.gov/8985785","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21398278","id":"PMC_21398278","title":"Genetic dissection of the Gpnmb network in the eye.","date":"2011","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/21398278","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27836549","id":"PMC_27836549","title":"Glycoprotein nonmetastatic melanoma protein B (GPNMB) promotes the progression of brain glioblastoma via Na+/K+-ATPase.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/27836549","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33706413","id":"PMC_33706413","title":"N-glycosylated GPNMB ligand independently activates mutated EGFR signaling and promotes metastasis in NSCLC.","date":"2021","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/33706413","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35914373","id":"PMC_35914373","title":"miR-532-3p suppresses proliferation and invasion of ovarian cancer cells via GPNMB/HIF-1α/HK2 axis.","date":"2022","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/35914373","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29290481","id":"PMC_29290481","title":"DLG2, but not TMEM229B, GPNMB, and ITGA8 polymorphism, is associated with Parkinson's disease in a Taiwanese population.","date":"2017","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/29290481","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12540541","id":"PMC_12540541","title":"The msbB mutant of Neisseria meningitidis strain NMB has a defect in lipooligosaccharide assembly and transport to the outer membrane.","date":"2003","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/12540541","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31498430","id":"PMC_31498430","title":"Transcriptome analysis reveals GPNMB as a potential therapeutic target for gastric cancer.","date":"2019","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31498430","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39455836","id":"PMC_39455836","title":"Bone-marrow macrophage-derived GPNMB protein binds to orphan receptor GPR39 and plays a critical role in cardiac repair.","date":"2024","source":"Nature cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/39455836","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30793225","id":"PMC_30793225","title":"Glycoprotein Nonmetastatic Melanoma Protein B (GPNMB) Ameliorates the Inflammatory Response in Periodontal Disease.","date":"2019","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/30793225","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38566120","id":"PMC_38566120","title":"Tumor associated microglia/macrophages utilize GPNMB to promote tumor growth and alter immune cell infiltration in glioma.","date":"2024","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/38566120","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15684612","id":"PMC_15684612","title":"Cloning and characterization of the 5' flanking region of the HGFIN gene indicate a cooperative role among p53 and cytokine-mediated transcription factors: relevance to cell cycle regulation.","date":"2005","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/15684612","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38037070","id":"PMC_38037070","title":"Progranulin and GPNMB: interactions in endo-lysosome function and inflammation in neurodegenerative disease.","date":"2023","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/38037070","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38048667","id":"PMC_38048667","title":"PCSK9 inhibitor protects against ischemic cerebral injury by attenuating inflammation via the GPNMB/CD44 pathway.","date":"2023","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38048667","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37919457","id":"PMC_37919457","title":"GPNMB Ameliorates Neuroinflammation Via the Modulation of AMPK/NFκB Signaling Pathway After SAH in Mice.","date":"2023","source":"Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37919457","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36566014","id":"PMC_36566014","title":"A novel molecular mechanism of vascular fibrosis in Takayasu arteritis: macrophage-derived GPNMB promoting adventitial fibroblast extracellular matrix production in the aorta.","date":"2022","source":"Translational research : the journal of laboratory and clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36566014","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7882024","id":"PMC_7882024","title":"Characterization of a triple opioid system in the human neuroblastoma NMB cell line.","date":"1994","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/7882024","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33947460","id":"PMC_33947460","title":"Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer's disease.","date":"2021","source":"Alzheimer's research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33947460","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31127873","id":"PMC_31127873","title":"Role of the kringle-like domain in glycoprotein NMB for its tumorigenic potential.","date":"2019","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/31127873","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35158847","id":"PMC_35158847","title":"TROP-2, Nectin-4, GPNMB, and B7-H3 Are Potentially Therapeutic Targets for Anaplastic Thyroid Carcinoma.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/35158847","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28939899","id":"PMC_28939899","title":"GPNMB Induces BiP Expression by Enhancing Splicing of BiP Pre-mRNA during the Endoplasmic Reticulum Stress Response.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28939899","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33986446","id":"PMC_33986446","title":"Quantitative trait locus mapping identifies the Gpnmb gene as a modifier of mouse macrophage lysosome function.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33986446","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34923085","id":"PMC_34923085","title":"Proteomic analysis of alcohol-associated hepatitis reveals glycoprotein NMB (GPNMB) as a novel hepatic and serum biomarker.","date":"2021","source":"Alcohol (Fayetteville, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/34923085","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34464706","id":"PMC_34464706","title":"Genetic ablation of Gpnmb does not alter synuclein-related pathology.","date":"2021","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/34464706","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38219952","id":"PMC_38219952","title":"Glycoprotein Nonmetastatic Melanoma Protein B (GPNMB) Immunohistochemistry Can Be a Useful Ancillary Tool to Identify Perivascular Epithelioid Cell Tumor.","date":"2024","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/38219952","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29428978","id":"PMC_29428978","title":"Overexpression of GPNMB predicts an unfavorable outcome of epithelial ovarian cancer.","date":"2018","source":"Archives of gynecology and obstetrics","url":"https://pubmed.ncbi.nlm.nih.gov/29428978","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34673297","id":"PMC_34673297","title":"Adaptive resistance in tumors to anti-PD-1 therapy through re-immunosuppression by upregulation of GPNMB expression.","date":"2021","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34673297","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30671053","id":"PMC_30671053","title":"A Host Factor GPNMB Restricts Porcine Circovirus Type 2 (PCV2) Replication and Interacts With PCV2 ORF5 Protein.","date":"2019","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/30671053","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37934943","id":"PMC_37934943","title":"Roles of Activin A and Gpnmb in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).","date":"2024","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/37934943","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25663982","id":"PMC_25663982","title":"Differential expression of glycoprotein non-metastatic melanoma protein B (GPNMB) involved in trichostatin A-induced apoptosis in gastric cancer.","date":"2014","source":"International journal of clinical and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25663982","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39992792","id":"PMC_39992792","title":"GPNMB and ATP6V1A interact to mediate microglia phagocytosis of multiple types of pathological particles.","date":"2025","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/39992792","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34207849","id":"PMC_34207849","title":"Functional Domains and Evolutionary History of the PMEL and GPNMB Family Proteins.","date":"2021","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34207849","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28689015","id":"PMC_28689015","title":"The laminin-derived peptide C16 regulates GPNMB expression and function in breast cancer.","date":"2017","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/28689015","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27634552","id":"PMC_27634552","title":"Effects of MC4R, FTO, and NMB gene variants to obesity, physical activity, and eating behavior phenotypes.","date":"2016","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/27634552","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25064009","id":"PMC_25064009","title":"Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease.","date":"2014","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25064009","citation_count":1512,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"31675496","id":"PMC_31675496","title":"Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma.","date":"2019","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/31675496","citation_count":1200,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26751287","id":"PMC_26751287","title":"The LINK-A lncRNA activates normoxic HIF1α signalling in triple-negative breast cancer.","date":"2016","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/26751287","citation_count":466,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16247014","id":"PMC_16247014","title":"The response of autologous T cells to a human melanoma is dominated by mutated neoantigens.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16247014","citation_count":357,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25658639","id":"PMC_25658639","title":"Glioma-associated microglia/macrophages display an expression profile different from M1 and M2 polarization and highly express Gpnmb and Spp1.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25658639","citation_count":335,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12975309","id":"PMC_12975309","title":"The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment.","date":"2003","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/12975309","citation_count":285,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15231748","id":"PMC_15231748","title":"Functional proteomics mapping of a human signaling pathway.","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15231748","citation_count":247,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23898208","id":"PMC_23898208","title":"Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23898208","citation_count":235,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7814155","id":"PMC_7814155","title":"nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts.","date":"1995","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/7814155","citation_count":232,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12853948","id":"PMC_12853948","title":"The DNA sequence of human chromosome 7.","date":"2003","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/12853948","citation_count":188,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20215530","id":"PMC_20215530","title":"Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer.","date":"2010","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/20215530","citation_count":160,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12690205","id":"PMC_12690205","title":"Human chromosome 7: DNA sequence and biology.","date":"2003","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/12690205","citation_count":154,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17081065","id":"PMC_17081065","title":"Proteomic and bioinformatic characterization of the biogenesis and function of melanosomes.","date":"2006","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/17081065","citation_count":150,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"30397336","id":"PMC_30397336","title":"Identification of phagocytosis regulators using magnetic genome-wide CRISPR screens.","date":"2018","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30397336","citation_count":146,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16609006","id":"PMC_16609006","title":"Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme.","date":"2006","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/16609006","citation_count":143,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17951401","id":"PMC_17951401","title":"Osteoactivin promotes breast cancer metastasis to bone.","date":"2007","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/17951401","citation_count":141,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"30340518","id":"PMC_30340518","title":"Glycoprotein NMB: a novel Alzheimer's disease associated marker expressed in a subset of activated microglia.","date":"2018","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/30340518","citation_count":123,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12643545","id":"PMC_12643545","title":"Proteomic analysis of early melanosomes: identification of novel melanosomal proteins.","date":"2003","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/12643545","citation_count":121,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"30992322","id":"PMC_30992322","title":"A Human Organotypic Microfluidic Tumor Model Permits Investigation of the Interplay between Patient-Derived Fibroblasts and Breast Cancer Cells.","date":"2019","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30992322","citation_count":120,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20379614","id":"PMC_20379614","title":"Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score.","date":"2010","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/20379614","citation_count":108,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20056711","id":"PMC_20056711","title":"Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome-specific and proteolytically released protein.","date":"2010","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/20056711","citation_count":99,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12176896","id":"PMC_12176896","title":"Identification of the genes differentially expressed in human dendritic cell subsets by cDNA subtraction and microarray analysis.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12176896","citation_count":96,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"31701227","id":"PMC_31701227","title":"Proteomics in cerebrospinal fluid and spinal cord suggests UCHL1, MAP2 and GPNMB as biomarkers and underpins importance of transcriptional pathways in amyotrophic lateral sclerosis.","date":"2019","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/31701227","citation_count":95,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"30149180","id":"PMC_30149180","title":"The glycoprotein GPNMB is selectively elevated in the substantia nigra of Parkinson's disease patients and increases after lysosomal stress.","date":"2018","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/30149180","citation_count":92,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"31586073","id":"PMC_31586073","title":"The midbody interactome reveals unexpected roles for PP1 phosphatases in cytokinesis.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31586073","citation_count":74,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53405,"output_tokens":9071,"usd":0.14814},"stage2":{"model":"claude-opus-4-6","input_tokens":13032,"output_tokens":4011,"usd":0.248152},"total_usd":0.867187,"stage1_batch_id":"msgbatch_01DzrsgVgYngY1hvM3DU1yF2","stage2_batch_id":"msgbatch_01KA9b7iRzKFdhoBUT7vCvSe","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":67195,"output_tokens":11671,"usd":0.188325},"round2_rules_fired":"R2","round2_stage2":{"model":"claude-opus-4-6","input_tokens":16016,"output_tokens":4332,"usd":0.28257}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2007,\n      \"finding\": \"GPNMB acts as a negative regulator of macrophage inflammatory responses: overexpression in RAW264.7 cells reduces LPS-induced IL-6, IL-12p40, and NO production; upon IFN-γ/LPS activation, GPNMB translocates from the Golgi apparatus to peripheral vesicular compartments.\",\n      \"method\": \"Epitope-tagged overexpression, cytokine ELISA, NO assay, immunofluorescence colocalization with Golgi marker; DBA mouse loss-of-function validation\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (overexpression, KO mouse, cytokine assays, localization) in a single study, replicated by genetic model\",\n      \"pmids\": [\"17475886\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ADAM10 is the sheddase responsible for releasing the GPNMB ectodomain from breast cancer cell surfaces; the shed ectodomain promotes endothelial cell migration in vitro.\",\n      \"method\": \"siRNA knockdown of candidate sheddases, immunoblot, ELISA, endothelial migration assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal siRNA knockdown of multiple sheddases identified ADAM10, functional validation with shed ECD\",\n      \"pmids\": [\"20711474\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"GPNMB attenuates astrocyte-mediated neuroinflammation through the CD44 receptor: recombinant GPNMB reduces cytokine-induced iNOS, NO, ROS, and IL-6 in astrocytes, and this anti-inflammatory effect is abolished in primary astrocytes from CD44 knockout mice.\",\n      \"method\": \"Recombinant protein treatment, qPCR, NO/ROS assays, CD44-KO primary astrocytes\",\n      \"journal\": \"Journal of neuroinflammation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function in CD44-KO primary cells orthogonally validated the receptor requirement alongside gain-of-function\",\n      \"pmids\": [\"29519253\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GPNMB coimmunoprecipitates and colocalizes with α-synuclein; loss of GPNMB in iPSC-derived neurons impairs internalization of α-synuclein fibrils and the development of α-synuclein pathology.\",\n      \"method\": \"Co-IP, immunofluorescence colocalization, iPSC-derived neuron loss-of-function\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP plus functional consequence in human iPSC neurons with multiple readouts\",\n      \"pmids\": [\"35981040\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"MITF transcriptionally regulates GPNMB expression via a conserved M-box element in the GPNMB promoter: MITF binds the M-box by EMSA (supershifted by anti-MITF antibody), transactivates the GPNMB promoter in reporter assays, and mutation of the M-box abolishes both binding and transactivation.\",\n      \"method\": \"EMSA, luciferase reporter gene assay, site-directed mutagenesis, microarray expression profiling\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro binding assay plus mutagenesis plus reporter assay with multiple controls\",\n      \"pmids\": [\"18313864\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"GPNMB is a MITF-dependent melanoblast gene; a conserved enhancer element (GPNMB-MCS3) containing two MITF consensus sites drives GPNMB expression in melanoblasts, and deletion of the 5'-most MITF site dramatically reduces enhancer activity.\",\n      \"method\": \"Luciferase reporter assay, in vivo enhancer transgenic assay, genome-wide MITF binding site annotation\",\n      \"journal\": \"Pigment cell & melanoma research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis of binding site plus in vivo transgenic validation\",\n      \"pmids\": [\"18983539\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"DC-HIL/GPNMB expressed on melanoma cells inhibits activation of tumor-reactive T cells by binding syndecan-4 (SD-4) on activated T cells; knockdown of DC-HIL in B16F10 melanoma reduces in vivo tumor growth in immunocompetent but not immunodeficient mice, and blocking SD-4 enhances CD8+ T cell reactivity to melanoma antigens.\",\n      \"method\": \"siRNA knockdown, in vivo syngeneic tumor growth, in vitro T-cell activation assay, SD-4 blocking antibody\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with defined immune-evasion phenotype, confirmed by receptor-blocking experiment\",\n      \"pmids\": [\"20570888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"GPNMB promotes breast cancer growth via upregulation of neuropilin-1 (NRP-1) that potentiates VEGF signaling, and promotes metastasis via RGD-motif-dependent binding to α5β1 integrin, activating Src and FAK signaling; the cytoplasmic tail is required for tumor growth but only the RGD motif is required for lung metastasis.\",\n      \"method\": \"RGD and cytoplasmic tail mutants, siRNA knockdown of NRP-1, in vivo orthotopic tumor and metastasis models, integrin co-immunoprecipitation, phospho-Src/FAK immunoblot\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — domain mutagenesis plus Co-IP plus in vivo functional validation with multiple orthogonal methods\",\n      \"pmids\": [\"25772243\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Lysosomal stress (induced by palmitate, chloroquine, or mTORC1 inhibition) activates MITF nuclear translocation and drives GPNMB transcription in macrophages; MITF knockdown abolishes GPNMB induction, placing GPNMB downstream of the mTORC1-MITF axis.\",\n      \"method\": \"Chemical inducers of lysosomal stress, shRNA-mediated MITF knockdown, nuclear fractionation, RAW264.7 cell model, ATM macrophage isolation\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistatic knockdown + multiple inducers + primary cell validation\",\n      \"pmids\": [\"24789918\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"MITF drives GPNMB expression in dendritic cells via inhibition of the PI3K/Akt pathway, which activates GSK3β and promotes MITF nuclear translocation; a small-molecule MITF inhibitor reduces GPNMB mRNA and protein, and exogenous SD-4 (GPNMB T-cell ligand) restores the stimulatory capacity of DCs.\",\n      \"method\": \"PI3K/Akt inhibitors, GSK3β activation assay, MITF inhibitor, qPCR/immunoblot, MLR assay\",\n      \"journal\": \"Cell communication and signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological dissection of pathway with multiple inhibitors and functional T-cell readout\",\n      \"pmids\": [\"25889792\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GPNMB is a direct transcriptional target of TFE3 fusion proteins in translocation RCC; PRCC-TFE3 transgenic mouse kidneys show elevated Gpnmb expression, and TSC2 loss in cell lines upregulates GPNMB in a MiT/TFE- and mTORC1-dependent fashion.\",\n      \"method\": \"Transgenic mouse model, CRISPR-Cas9 TSC2/TFE3/TFEB knockout cell lines, IHC, qPCR\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function (CRISPR) plus in vivo transgenic model\",\n      \"pmids\": [\"31043488\", \"35072947\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Macrophage-secreted OA/GPNMB promotes mesenchymal stem cell survival, proliferation, and migration through CD44 receptor, activating ERK and AKT signaling pathways; loss-of-function and rescue studies confirmed CD44 as the mediating receptor.\",\n      \"method\": \"Loss-of-function siRNA, rescue overexpression, phospho-ERK/AKT immunoblot, cell viability and migration assays\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function plus rescue experiment with defined downstream pathway\",\n      \"pmids\": [\"26442636\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Macrophage-derived soluble GPNMB activates tumor cells via CD44 receptor to express IL-33 and its receptor IL-1RL1, inducing cancer stem cell self-renewal and metastatic phenotype; recombinant IL-33 alone is sufficient to induce tumor spheroid formation.\",\n      \"method\": \"Mouse tumor models with Gpnmb-mutant DBA/2J mice, recombinant GPNMB treatment, CD44 receptor blocking, IL-33 recombinant protein rescue\",\n      \"journal\": \"Cellular & molecular immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic model plus mechanistic receptor and cytokine rescue experiments\",\n      \"pmids\": [\"32728200\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Gpnmb is secreted from liver (processing of membrane protein to secreted form driven by inhibition of SREBP pathway) and stimulates lipogenesis in white adipose tissue, exacerbating diet-induced obesity and insulin resistance; neutralizing antibody or liver-specific knockdown improves metabolic parameters.\",\n      \"method\": \"Liver-specific knockdown, transgenic overexpression, neutralizing antibody, adipose tissue lipogenesis assays, mouse diet-induced obesity model\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic and pharmacological interventions with clear metabolic phenotypes\",\n      \"pmids\": [\"32694855\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"GPNMB has a neuroprotective role in ALS: glycosylation of GPNMB is inhibited by interaction with mutant SOD1(G93A), increasing motor neuron vulnerability; extracellular fragments of GPNMB secreted from activated astrocytes attenuate SOD1(G93A) neurotoxicity in neural cells.\",\n      \"method\": \"Co-immunoprecipitation, glycosylation assay, NSC34 cell survival assay, DNA microarray\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP showing SOD1 interaction plus functional neuroprotection assay, single lab\",\n      \"pmids\": [\"22891158\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Recombinant GPNMB exerts neuroprotection against cerebral ischemia-reperfusion injury via phosphorylation of ERK1/2 and Akt; GPNMB transgenic mice show reduced infarct volume and increased p-ERK1/2 and p-Akt.\",\n      \"method\": \"GPNMB transgenic mice, MCAO model, Western blot for p-ERK1/2/p-Akt, recombinant GPNMB treatment\",\n      \"journal\": \"Neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — transgenic gain-of-function plus recombinant protein, but mechanistic link to ERK/Akt is correlative\",\n      \"pmids\": [\"25010402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"GPNMB is critical for melanosome formation in melanocytes: siRNA silencing of GPNMB in PIG1 melanocytes sharply reduces the total number of melanosomes (by TEM) and attenuates expression of tyrosinase, Trp1, Pmel17/gp100, and OA1, in a MITF-independent fashion.\",\n      \"method\": \"siRNA knockdown, transmission electron microscopy, Western blot, immunofluorescence, qRT-PCR\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal readouts (TEM ultrastructure, multiple protein/mRNA markers) establishing functional role\",\n      \"pmids\": [\"22912767\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ET-1 induces melanogenesis via the MITF-GPNMB pathway: MITF siRNA inhibits GPNMB expression and blocks ET-1-induced melanogenesis; GPNMB siRNA reduces melanosomes and melanin; these effects establish GPNMB as a downstream effector of MITF in ET-1-induced pigmentation.\",\n      \"method\": \"siRNA (MITF and GPNMB), melanin quantification, melanosome counting, qPCR, Western blot\",\n      \"journal\": \"BMB reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistatic siRNA knockdown placing GPNMB downstream of MITF, single lab\",\n      \"pmids\": [\"23884103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"GPNMB stimulates osteogenesis via FGFR-1 signaling: recombinant GPNMB promotes osteoblast differentiation and endothelial cell migration/tube formation dose-dependently; FGFR-1 siRNA or inhibitor (SU5402) abolishes GPNMB-induced effects in vitro and in a cranial defect in vivo model.\",\n      \"method\": \"Recombinant protein, siRNA knockdown, FGFR-1 pharmacological inhibition, in vitro differentiation/migration assays, in vivo cranial defect model\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological and genetic loss-of-function of receptor plus in vivo validation\",\n      \"pmids\": [\"23794283\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"GPNMB interacts with Na+/K+-ATPase α subunits to activate PI3K/Akt and MEK/ERK pathways and promote glioma growth; ouabain (Na+/K+-ATPase inhibitor) suppresses GPNMB-driven tumor growth in transgenic mice overexpressing GPNMB.\",\n      \"method\": \"Co-IP, GPNMB transgenic mice, orthotopic glioma model, ouabain pharmacological inhibition, phospho-PI3K/Akt/ERK immunoblot\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP plus pharmacological inhibition of identified interactor, single lab\",\n      \"pmids\": [\"27836549\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"GPNMB promotes motor neuron cell survival against mutant TDP-43 stress by activating ERK1/2 and Akt pathways; recombinant GPNMB rescues NSC34 motor neurons from mutant TDP-43-induced cell death and serum-free stress, increasing p-ERK1/2 and p-Akt.\",\n      \"method\": \"Mutant TDP-43 plasmid transfection, recombinant GPNMB treatment, cell viability assay, phospho-ERK1/2/Akt Western blot\",\n      \"journal\": \"Journal of neuroscience research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function with defined signaling readout, single lab\",\n      \"pmids\": [\"27935101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Under ER stress, GPNMB relocates to the nucleus and promotes splicing of BiP pre-mRNA (independent of IRE1, PERK, and ATF6 pathways), increasing BiP protein levels and protecting neurons; GPNMB transgenic mice show increased BiP and reduced infarction after MCAO.\",\n      \"method\": \"Thapsigargin-induced ER stress, nuclear fractionation, BiP pre-mRNA splicing assay, transgenic GPNMB mice, MCAO model\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic nuclear relocalization with specific pre-mRNA splicing readout plus in vivo validation\",\n      \"pmids\": [\"28939899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MITF inhibition represses GPNMB expression in a dose-dependent manner in dendritic cells; BRAF/MEK inhibitor treatment of melanoma cells increases MITF and consequently upregulates GPNMB via MITF; siRNA knockdown of MITF abolishes treatment-induced GPNMB upregulation.\",\n      \"method\": \"BRAF/MEK inhibitors, siRNA-mediated MITF knockdown, RT-qPCR, immunoblot, FACS, patient biopsy analysis\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — siRNA epistasis plus pharmacological induction, validated in patient biopsies\",\n      \"pmids\": [\"27515299\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The Takayasu arteritis risk allele at IL6 locus (rs2069837) preferentially recruits the MEF2-HDAC repressive complex via long-range chromatin looping (~520 kb) to repress GPNMB expression in monocyte-derived macrophages; HDAC inhibition reverses this suppression.\",\n      \"method\": \"EMSA, DNA affinity precipitation + mass spectrometry, luciferase reporter, chromosome conformation capture (3C), primary human macrophages, HDAC inhibitor\",\n      \"journal\": \"Annals of the rheumatic diseases\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal epigenomic methods (3C, EMSA, ChIP surrogate) identifying specific complex and chromatin loop\",\n      \"pmids\": [\"31315839\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GPNMB is a causal modifier of macrophage lysosome function: siRNA knockdown of Gpnmb in AKR/J macrophages decreases lysosome function; CRISPR-Cas9 deletion in RAW264.7 cells confirms this; GPNMB recruits LC3 to autophagosomes for lysosome fusion, and the DBA/2J nonsense variant in Gpnmb explains the lysosomal defect in this strain.\",\n      \"method\": \"QTL mapping, siRNA knockdown, CRISPR-Cas9 deletion, lysosome function dual-labeled fluorescent indicator assay, genetic rescue using DBA/2J-Gpnmb+/SjJ substrain\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic loss-of-function approaches (siRNA, CRISPR, natural variant rescue) with quantitative lysosome function assay\",\n      \"pmids\": [\"33986446\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Loss-of-function mutations in GPNMB (nonsense/frameshift) cause autosomal-recessive amyloidosis cutis dyschromica in humans; GPNMB is expressed in all epidermal cells (highest in melanocytes), and its loss leads to amyloid deposition, melanocyte loss, and keratinocyte fibrillary aggregates.\",\n      \"method\": \"Human genetics (compound heterozygosity/homozygosity of GPNMB truncating alleles), immunofluorescence of skin biopsies, electron microscopy\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function in humans with tissue-level mechanistic characterization\",\n      \"pmids\": [\"29336782\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Macrophage-derived GPNMB activates adventitial fibroblasts via integrin αVβ1 receptor and downstream Akt/Erk signaling to promote extracellular matrix production and vascular fibrosis in Takayasu arteritis.\",\n      \"method\": \"Co-IP, siRNA/inhibitor intervention for integrin αVβ1, phospho-Akt/Erk immunoblot, GPNMB-overexpressing macrophage conditioned media on fibroblasts\",\n      \"journal\": \"Translational research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — receptor identified by Co-IP and siRNA/inhibitor, downstream signaling confirmed, single lab\",\n      \"pmids\": [\"36566014\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Macrophage-derived GPNMB captured by fibrotic ECM activates resident fibroblasts via the CD44/Serpinb2 pathway, promoting pulmonary fibrosis; GPNMB-neutralizing antibodies or macrophage depletion attenuate fibroblast activation in fibrotic ECM from silica-instilled mice.\",\n      \"method\": \"ECM proteomics, GPNMB-neutralizing antibody, macrophage depletion, CD44 expression analysis, ex vivo fibrotic ECM culture system\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — neutralizing antibody and macrophage depletion with defined pathway, single lab\",\n      \"pmids\": [\"36732560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GPNMB overexpression ameliorates Alzheimer's disease-like pathology in APP/PS1 mice by enhancing autophagy via suppression of mTOR signaling, reducing Aβ deposition; the autophagy inhibitor 3-MA abolishes GPNMB's beneficial effects on Aβ clearance.\",\n      \"method\": \"GPNMB overexpression (gain-of-function), 3-MA autophagy inhibitor rescue, TEM/immunofluorescence for autophagy markers, p-mTOR immunoblot, APP/PS1 mouse behavioral assays\",\n      \"journal\": \"Neuroscience letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological epistasis (3-MA rescue) plus signaling readout, single lab\",\n      \"pmids\": [\"34695452\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"N-glycosylation at Asn134 (N134) of GPNMB is required for its binding to the C-terminus of mutated EGFR; GPNMB activates mutated EGFR in a ligand-independent manner, inducing phosphorylation at Y845 and downstream STAT3 signaling to promote metastasis; depleting N134 glycosylation abolishes EGFR binding.\",\n      \"method\": \"Membrane proteomics, Co-IP, glycosylation mutant (N134A), phospho-EGFR Y845/STAT3 immunoblot, siRNA, in vivo metastasis assay\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — site-specific mutagenesis (N134A) plus Co-IP plus signaling assay defining molecular mechanism\",\n      \"pmids\": [\"33706413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"DC-HIL/GPNMB-expressing myeloid-derived suppressor cells (MDSCs) and soluble DC-HIL negatively regulate tumor response to anti-PD-L1 therapy; deletion of host-derived DC-HIL gene converts anti-PD-L1-resistant tumors to responsive ones, and infusion of DC-HIL+ MDSCs reverses responsiveness.\",\n      \"method\": \"Genetic DC-HIL deletion in host mice, MDSC adoptive transfer, anti-PD-L1 treatment, experimental lung metastasis model\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function plus cellular rescue (MDSC transfer) defining checkpoint function\",\n      \"pmids\": [\"31822499\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GPNMB expression in macrophages promotes M2 polarization: siRNA knockdown of Gpnmb in bone marrow-derived macrophages inhibits M2 polarization and IL-10/TGF-β secretion while promoting M1 polarization and IL-1β/TNF-α production; the IL-4-STAT6 pathway mediates M2-promoting effect of GPNMB.\",\n      \"method\": \"siRNA knockdown, ELISA for cytokines, flow cytometry for M1/M2 markers, STAT6 pathway analysis\",\n      \"journal\": \"Cellular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA knockdown with defined phenotypic and signaling readouts, single lab\",\n      \"pmids\": [\"28433199\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GPNMB ameliorates neuroinflammation after subarachnoid hemorrhage via the AMPK/NFκB signaling pathway: recombinant GPNMB increases p-AMPK, suppresses p-NFκB and inflammatory cytokines (IL-1β, IL-6, TNF-α); the AMPK inhibitor dorsomorphin reverses these effects.\",\n      \"method\": \"tMCAO/SAH mouse model, intracerebroventricular recombinant GPNMB injection, dorsomorphin pharmacological inhibition, Western blot, ELISA, BBB integrity assay\",\n      \"journal\": \"Journal of neuroimmune pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological epistasis with inhibitor rescue, single lab\",\n      \"pmids\": [\"37919457\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Bone-marrow-derived macrophages are the main source of GPNMB in injured hearts; GPNMB deficiency leads to increased mortality and cardiac dysfunction after MI while viral delivery of GPNMB improves heart function; GPR39 was identified as a receptor for circulating GPNMB, and its absence negates GPNMB's beneficial effects.\",\n      \"method\": \"Lineage tracing, bone-marrow transplantation, genetic GPNMB loss-of-function, viral GPNMB delivery, GPR39 KO mice, single-cell transcriptomics, cardiac functional readouts\",\n      \"journal\": \"Nature cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal genetic models (loss-of-function, receptor KO, rescue) with defined functional cardiac phenotypes\",\n      \"pmids\": [\"39455836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"GPNMB functions in microglial phagocytosis by wrapping engulfed pathogenic particles and presenting them to lysosomes through direct interaction with lysosomal vacuolar-type proton ATPase catalytic subunit A (ATP6V1A); GPNMB deficiency impairs both phagocytic engulfment and lysosomal degradation, and activating ATP6V1A rescues GPNMB-deficiency-caused phagocytosis impairment.\",\n      \"method\": \"Genetic ablation of GPNMB, Co-IP (GPNMB-ATP6V1A), live imaging of internalization, phagocytosis assays, ATP6V1A activator rescue\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP identifying molecular partner plus genetic loss-of-function plus pharmacological rescue\",\n      \"pmids\": [\"39992792\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GPNMB upregulates MMP-3 expression in LPS-activated microglia (BV2 cells); GPNMB siRNA or MMP-3 inhibitor suppresses TNF-α, IL-1β, iNOS, and NO in activated microglia, defining GPNMB as an upstream regulator of MMP-3-mediated neuroinflammation.\",\n      \"method\": \"siRNA knockdown, MMP-3 inhibitor, RT-PCR, Western blot, ELISA for TNF-α/IL-1β, NO measurement\",\n      \"journal\": \"Journal of molecular neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistatic siRNA and pharmacological inhibitor, single lab\",\n      \"pmids\": [\"24682924\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Cell surface-exposed GPNMB on dormant breast cancer cells confers cancer stem cell-like properties; mutation of the hemITAM tyrosine in the cytoplasmic tail (YF mutant) abolishes tumorigenic activity, and wild-type but not YF GPNMB induces sphere-forming capacity.\",\n      \"method\": \"3D sphere culture, cell-surface FACS isolation, mutant GPNMB (YF), sphere-forming frequency assay, qPCR for CSC markers\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — domain mutagenesis with defined functional readout, single lab\",\n      \"pmids\": [\"30224376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The kringle-like domain (KLD) in the GPNMB extracellular domain is required for its tumorigenic activity: GPNMB(ΔKLD) loses sphere/tumor formation and cell migration-promoting activities without affecting subcellular localization, hemITAM tyrosine phosphorylation (in overexpression), or homo-oligomerization.\",\n      \"method\": \"Domain deletion mutagenesis, sphere formation assay, in vivo tumor formation, cell migration assay, subcellular localization, Co-IP for homo-oligomerization\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — domain mutagenesis with multiple functional assays, single lab\",\n      \"pmids\": [\"31127873\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"GPNMB transgenic overexpression protects against MPTP-induced dopaminergic neurodegeneration and reduces gliosis; recombinant GPNMB attenuates LPS-induced inflammation in primary microglia.\",\n      \"method\": \"GPNMB transgenic mice, MPTP model of PD, dopaminergic neuron counting, microglial morphology analysis, recombinant GPNMB treatment of primary microglia\",\n      \"journal\": \"Molecular neurobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — transgenic gain-of-function with defined neuroprotection phenotype plus recombinant protein in primary cells\",\n      \"pmids\": [\"32436108\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GPNMB is a type I transmembrane glycoprotein that functions as a multi-receptor ligand—binding syndecan-4 (on T cells), CD44 (on astrocytes, MSCs, fibroblasts), integrins α5β1 and αVβ1, mutated EGFR (via N134-glycosylation), Na+/K+-ATPase α subunits, and the orphan receptor GPR39—whose ectodomain is shed by ADAM10 to act in paracrine fashion; intracellularly, GPNMB is transcriptionally regulated by MITF (via a conserved M-box) downstream of the mTORC1-GSK3β axis, promotes lysosomal/autophagic function through interaction with ATP6V1A, translocates to the nucleus under ER stress to enhance BiP pre-mRNA splicing, and suppresses inflammation in macrophages and astrocytes while promoting cancer immune evasion through SD-4-mediated T-cell inhibition.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"GPNMB (nmb) was originally identified as a novel gene encoding a putative transmembrane glycoprotein with homology to the pMEL17 melanocyte-specific protein precursor, preferentially expressed in low-metastatic human melanoma cell lines; transfection of partial nmb cDNA into highly metastatic melanoma cells reduced subcutaneous tumor growth and metastatic potential in nude mice.\",\n      \"method\": \"Subtractive cDNA library, transfection/overexpression in vivo xenograft model\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — original discovery with functional validation by transfection and in vivo model, single lab\",\n      \"pmids\": [\"7814155\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"GPNMB (Osteoactivin) acts as a negative regulator of macrophage inflammatory responses: overexpression in RAW264.7 cells reduced LPS-induced IL-6, IL-12p40, and NO production; upon IFN-γ/LPS activation, GPNMB translocated from the Golgi apparatus (where it co-localized with coat protein beta) to peripheral vesicular compartments; DBA mice with an inactivating Gpnmb point mutation exhibited elevated proinflammatory cytokines in response to LPS.\",\n      \"method\": \"Epitope-tagged overexpression, co-localization imaging (Golgi marker), cytokine ELISA, DBA mutant mouse model\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (overexpression, subcellular localization, loss-of-function mouse model), independently replicated concept\",\n      \"pmids\": [\"17475886\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Osteoactivin/GPNMB promotes breast cancer bone metastasis; sustained GPNMB expression is required for invasion, and GPNMB overexpression elevates matrix metalloproteinase-3 (MMP-3) levels, while siRNA depletion of GPNMB reduces MMP-3 expression, identifying MMP-3 as a downstream mediator.\",\n      \"method\": \"siRNA knockdown, forced overexpression, in vivo bone metastasis model (4T1 mammary carcinoma), gene expression profiling\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal gain/loss-of-function with defined molecular readout (MMP-3), in vivo validation\",\n      \"pmids\": [\"17951401\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"GPNMB expression is directly transcriptionally regulated by microphthalmia transcription factor (MITF) via a conserved M-box binding site in the GPNMB promoter; EMSA identified MITF binding to this site, mutation abolished binding and transactivation, and kinetics of GPNMB induction during osteoclastogenesis paralleled known MITF targets acp5 and clcn7; GPNMB co-localized with lysosomal/endocytic marker MAC-3/LAMP-2 in mature macrophages.\",\n      \"method\": \"EMSA, reporter gene assay with promoter mutation, microarray expression profiling, immunofluorescence co-localization\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct biochemical identification of transcription factor binding site with mutagenesis and reporter assay, replicated in multiple cell contexts\",\n      \"pmids\": [\"18313864\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Gpnmb is a MITF-dependent melanoblast-expressed gene; a conserved enhancer element (GPNMB-MCS3) containing two MITF consensus sites drives expression in melanoblasts in vivo, and deletion of the 5'-most MITF site dramatically reduces enhancer activity.\",\n      \"method\": \"Whole-genome MITF binding site annotation, luciferase reporter assay, transgenic in vivo enhancer analysis, Mitf mutant mouse expression studies\",\n      \"journal\": \"Pigment cell & melanoma research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vivo enhancer validation combined with mutagenesis and reporter assays\",\n      \"pmids\": [\"18983539\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ADAM10 is the sheddase responsible for proteolytic release of the GPNMB ectodomain (ECD) from breast cancer cell surfaces; siRNA-mediated knockdown of ADAM10 specifically blocked GPNMB ECD shedding, and the shed ECD promoted endothelial cell migration in vitro, identifying ectodomain shedding as a mechanism by which GPNMB promotes angiogenesis.\",\n      \"method\": \"Transient siRNA knockdown of candidate sheddases, immunoblot, ELISA, endothelial migration assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematic sheddase screen with siRNA, functional validation of shed ECD on endothelial migration\",\n      \"pmids\": [\"20711474\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"GPNMB (DC-HIL) expressed on melanoma cells inhibits activation of melanoma-reactive T cells by binding syndecan-4 (SD-4) on activated T cells; siRNA knockdown of GPNMB in B16F10 melanoma markedly reduced in vivo tumor growth in immunocompetent but not immunodeficient mice, and DC-HIL-knocked-down cells showed augmented capacity to activate melanoma-reactive T cells; blocking SD-4 enhanced CD8+ T cell reactivity to melanoma antigens.\",\n      \"method\": \"siRNA knockdown, in vivo tumor growth in immunocompetent vs. immunodeficient mice, T cell activation assays, SD-4 blocking experiments\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined cellular phenotype, mechanistic follow-up with receptor blocking, replicated across multiple assays\",\n      \"pmids\": [\"20570888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"GPNMB is a melanosomal protein enriched in mature (stage III-IV) melanosomes; it is released as a secreted form by ectodomain shedding from the largely Golgi-modified form, and the PKC and Ca2+ intracellular signaling pathways regulate GPNMB shedding.\",\n      \"method\": \"Subcellular fractionation, immunofluorescence, kinase inhibitor/signaling pathway pharmacology, ELISA for shed form\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct organelle localization with fractionation, mechanistic pathway identification for shedding regulation\",\n      \"pmids\": [\"20056711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"GPNMB silencing by siRNA sharply reduced the total number of melanosomes in melanocytes and attenuated expression of melanosomal proteins tyrosinase, Trp1, Pmel17/gp100, and OA1, demonstrating that GPNMB is critical for melanosome formation; this effect was MITF-independent. UVB radiation upregulated GPNMB expression in melanocytes.\",\n      \"method\": \"siRNA knockdown, transmission electron microscopy (melanosome counting), Western blotting, qPCR, immunofluorescence\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ultrastructural (TEM) and molecular validation of melanosome loss after GPNMB silencing\",\n      \"pmids\": [\"22912767\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"GPNMB glycosylation is inhibited by interaction with mutant SOD1(G93A) in motor neurons, increasing their vulnerability; extracellular fragments of GPNMB secreted from activated astrocytes attenuate neurotoxicity of SOD1(G93A) in neural cells, indicating a neuroprotective paracrine role for secreted GPNMB.\",\n      \"method\": \"Co-expression studies in NSC34 cells, glycosylation assays, recombinant GPNMB treatment, neurotoxicity assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — mechanistic findings from cell-based assays, single lab\",\n      \"pmids\": [\"22891158\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ET-1 (endothelin-1) triggers melanogenesis via the MITF-regulated GPNMB pathway: ET-1 increases MITF and GPNMB expression; siRNA knockdown of GPNMB reduces total melanosomes and melanin synthesis; siRNA knockdown of MITF suppresses GPNMB expression and ET-1-induced pigmentation, establishing GPNMB downstream of MITF in the ET-1 signaling axis.\",\n      \"method\": \"siRNA knockdown of GPNMB and MITF, melanin quantification, melanosome counting, Western blotting\",\n      \"journal\": \"BMB reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis established by double knockdown; single lab\",\n      \"pmids\": [\"23884103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"GPNMB stimulates osteogenesis and angiogenesis via FGFR-1 signaling: recombinant GPNMB dose-dependently induced osteoblast differentiation (ALP, OCN expression) from human bone marrow stromal cells and promoted endothelial proliferation, migration, and tube formation; pretreatment with FGFR-1 siRNA or inhibitor SU5402 abolished these effects; in a rodent cranial defect model, GPNMB-delivering scaffolds increased bone and vessel formation, reversed by combined SU5402.\",\n      \"method\": \"Recombinant protein treatment, siRNA knockdown of FGFR-1, FGFR-1 inhibitor, in vitro differentiation assays, in vivo cranial defect model\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (siRNA + inhibitor + in vivo), consistent mechanistic conclusion\",\n      \"pmids\": [\"23794283\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"In obese adipose tissue macrophages, lysosomal stress (induced by palmitate, chloroquine, or mTORC1 inhibitor Torin1) causes MITF nuclear translocation, which is absolutely required for GPNMB induction; shRNA knockdown of MITF abolished Gpnmb upregulation; in vivo, reduced mTORC1 activity in obese mouse adipose tissue macrophages coincided with increased nuclear MITF and elevated Gpnmb transcription, placing GPNMB downstream of mTORC1-MITF in lysosomal stress response.\",\n      \"method\": \"shRNA knockdown of MITF, mTORC1 inhibition, nuclear MITF localization imaging, gene expression in isolated ATMs\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic and pharmacological epistasis establishing mTORC1→MITF→GPNMB pathway, in vitro and in vivo\",\n      \"pmids\": [\"24789918\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GPNMB in LPS-activated microglia upregulates MMP-3 expression, which in turn promotes production of proinflammatory mediators (TNF-α, IL-1β, iNOS, NO); siRNA knockdown of GPNMB or MMP-3 inhibitor treatment suppressed these inflammatory mediators, establishing a GPNMB→MMP-3 axis in microglial inflammation.\",\n      \"method\": \"siRNA knockdown, MMP-3 inhibitor, ELISA for cytokines, RT-PCR and Western blotting\",\n      \"journal\": \"Journal of molecular neuroscience : MN\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis via siRNA and inhibitor, single lab\",\n      \"pmids\": [\"24682924\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GPNMB neuroprotection in cerebral ischemia-reperfusion injury is associated with phosphorylation of ERK1/2 and Akt; GPNMB transgenic mice showed reduced infarct volume and increased p-ERK1/2 and p-Akt by Western blotting; recombinant GPNMB (extracellular sequence) also decreased infarction volume, indicating the neuroprotective effect is mediated by the extracellular domain.\",\n      \"method\": \"GPNMB transgenic mouse model, middle cerebral artery occlusion, Western blotting for p-ERK1/2/p-Akt, recombinant GPNMB treatment\",\n      \"journal\": \"Neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — transgenic and recombinant protein approaches; downstream pathway by Western blot; single lab\",\n      \"pmids\": [\"25010402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"GPNMB cooperates with neuropilin-1 (NRP-1) to promote breast cancer tumor growth: GPNMB overexpression increases NRP-1 expression, potentiating VEGF signaling; NRP-1 is required for GPNMB-driven tumor growth but not metastasis. Additionally, GPNMB binds α5β1 integrin through its RGD motif, and this interaction activates Src and FAK signaling; RGD motif mutation impairs lung metastasis formation whereas both RGD motif and cytoplasmic tail are required for primary tumor growth.\",\n      \"method\": \"Forced overexpression, RNAseq, RGD motif mutagenesis, Co-IP/integrin complex pulldown, Src/FAK signaling assays, in vivo mammary tumor and metastasis models\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — domain mutagenesis, Co-IP, and in vivo validation with multiple genetic constructs\",\n      \"pmids\": [\"25772243\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"GPNMB transcription in dendritic cells is regulated by MITF downstream of PI3K/Akt inhibition: IL-10 and BCR-ABL TKIs (imatinib, nilotinib) inhibit PI3K/Akt, activating GSK3β, which leads to MITF phosphorylation and nuclear translocation; a MITF activity inhibitor reduced GPNMB mRNA and protein; PI3K/Akt inhibition-induced GPNMB overexpression reduced moDC stimulatory capacity in MLRs, rescued by adding the GPNMB T cell ligand syndecan-4.\",\n      \"method\": \"Small molecule inhibitors, MITF inhibitor, mRNA/protein quantification, mixed lymphocyte reaction\",\n      \"journal\": \"Cell communication and signaling : CCS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological epistasis establishing PI3K/Akt→GSK3β→MITF→GPNMB pathway; single lab\",\n      \"pmids\": [\"25889792\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Soluble Gpnmb ameliorated fat accumulation and fibrosis in obese liver in transgenic mice; Gpnmb concentrated in hepatic macrophages and stellate cells interacted with calnexin, which resulted in reduction of oxidative stress.\",\n      \"method\": \"Gpnmb transgenic mouse model (aP2 promoter), co-localization/interaction studies, oxidative stress assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — Co-interaction with calnexin shown in vivo context, single lab\",\n      \"pmids\": [\"26581806\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Recombinant GPNMB promotes MSC survival, proliferation, and migration via CD44 receptor, activating downstream ERK and AKT signaling pathways; loss-of-function and rescue studies demonstrated that M2 macrophage-secreted GPNMB mediates these MSC responses via CD44.\",\n      \"method\": \"Recombinant GPNMB treatment, loss-of-function (siRNA/antibody blocking), rescue studies, Western blotting for ERK/AKT phosphorylation\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function and rescue with defined pathway readout; single lab\",\n      \"pmids\": [\"26442636\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"GPNMB promotes brain glioblastoma progression via interaction with Na+/K+-ATPase α subunits, activating PI3K/Akt and MEK/ERK pathways; the interaction was identified in murine glioma models and human GBM tumors; ouabain (Na+/K+-ATPase inhibitor) suppressed GPNMB-driven glioma growth and blocked GPNMB-induced glioma cell migration.\",\n      \"method\": \"Co-immunoprecipitation, transgenic GPNMB overexpression mouse glioma model, pharmacological inhibition with ouabain, migration assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP identifying binding partner, pharmacological epistasis in vivo; single lab\",\n      \"pmids\": [\"27836549\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Recombinant GPNMB ameliorates motor neuron cell death induced by mutant TDP-43 (M337V, A315T) and serum-free stress via activation of ERK1/2 and Akt pathways; phosphorylated ERK1/2 and Akt were decreased by stress and rescued by recombinant GPNMB treatment in NSC34 motor neuron cells; GPNMB aggregates co-localize with TDP-43 aggregates in MAP-2-positive neurons in ALS spinal cord.\",\n      \"method\": \"Mutant TDP-43 plasmid transfection, recombinant GPNMB treatment, Western blotting for p-ERK1/2/p-Akt, immunohistochemistry co-localization in ALS patient tissue\",\n      \"journal\": \"Journal of neuroscience research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway identified by rescue experiment with recombinant protein; single lab\",\n      \"pmids\": [\"27935101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"GPNMB silencing via siRNA inhibits proliferation and metastasis of osteosarcoma cells (MG63, U2OS) by suppressing PI3K/Akt/mTOR signaling; IGF-1 (PI3K/AKT activator) reversed the suppressive effects, placing GPNMB upstream of PI3K/Akt/mTOR.\",\n      \"method\": \"siRNA knockdown, IGF-1 rescue, MTT proliferation and Transwell invasion assays, Western blotting for PI3K/Akt/mTOR pathway\",\n      \"journal\": \"Oncology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis via rescue experiment; single lab\",\n      \"pmids\": [\"29620278\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BRAF and MEK inhibitor treatment of melanoma cells induces GPNMB expression via MITF in a MITF-dependent manner (siRNA knockdown of MITF blocked treatment-induced GPNMB upregulation); GPNMB is expressed at the cell surface in MAPK inhibitor-treated cells and elevated in on-treatment biopsies from patients; combining MAPK inhibitors with CDX-011 (anti-GPNMB ADC) is more effective than MAPK inhibition alone in preclinical models.\",\n      \"method\": \"siRNA knockdown of MITF, RT-qPCR, immunoblot, FACS, serial patient biopsies, in vivo tumor models\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis (MITF siRNA) confirmed in cell lines and patient samples, in vivo validation\",\n      \"pmids\": [\"27515299\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GPNMB expression in dendritic cells is regulated by a Takayasu arteritis risk locus (rs2069837) in IL6 through long-range chromatin looping (~520 kb); the risk allele preferentially recruits MEF2-HDAC repressive complex, suppressing GPNMB expression in monocyte-derived macrophages; HDAC inhibition reversed this suppression.\",\n      \"method\": \"EMSA, DNA affinity precipitation + mass spectrometry, luciferase reporter assay, chromosome conformation capture (3C), HDAC inhibitor treatment in primary macrophages\",\n      \"journal\": \"Annals of the rheumatic diseases\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — 3C chromatin looping, biochemical identification of repressor complex by MS, functional validation with inhibitor; multiple orthogonal methods\",\n      \"pmids\": [\"31315839\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GPNMB induces BiP expression during ER stress by promoting splicing of BiP pre-mRNA; under ER stress, GPNMB relocates to the nucleus and specifically upregulates BiP mRNA through pre-mRNA splicing, acting independently of the three major ER stress transducers (IRE1, PERK, ATF6); GPNMB transgenic mice showed elevated BiP and reduced infarction after MCAO.\",\n      \"method\": \"Thapsigargin-induced ER stress, subcellular fractionation/nuclear localization imaging, mRNA splicing analysis, IRE1/PERK/ATF6 pathway inhibition, GPNMB transgenic mouse MCAO model\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — novel nuclear function identified with orthogonal pathway exclusion; single lab\",\n      \"pmids\": [\"28939899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Gpnmb promotes M2 macrophage polarization: siRNA knockdown of Gpnmb in bone marrow-derived macrophages inhibited M2 polarization and anti-inflammatory cytokines IL-10 and TGF-β, while promoting M1 polarization and pro-inflammatory cytokines IL-1β and TNF-α; IL-4-STAT6 pathway was identified as mechanistically involved in Gpnmb-promoted M2 polarization.\",\n      \"method\": \"siRNA knockdown, macrophage polarization assays, cytokine ELISA, STAT6 pathway analysis\",\n      \"journal\": \"Cellular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA epistasis with defined pathway readout; single lab\",\n      \"pmids\": [\"28433199\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"GPNMB exerts anti-inflammatory effects on astrocytes via CD44: recombinant GPNMB attenuated cytokine-induced iNOS, NO, ROS, and IL-6 in astrocytes; using primary mouse astrocytes from CD44 knockout mice, the anti-inflammatory effects of GPNMB were abolished, demonstrating CD44-mediated signaling.\",\n      \"method\": \"CD44 knockout primary astrocytes, recombinant GPNMB treatment, qPCR, NO and ROS measurement, immunofluorescence\",\n      \"journal\": \"Journal of neuroinflammation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout of receptor definitively establishes CD44-dependence; clean loss-of-function\",\n      \"pmids\": [\"29519253\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"GPNMB loss-of-function (truncating alleles) causes autosomal-recessive amyloidosis cutis dyschromica in humans; GPNMB is expressed in all epidermal cells with highest staining in melanocytes, and loss of GPNMB is associated with increased amyloid deposits in the dermis, infiltrating macrophages, and loss of melanocytes, implicating GPNMB in melanosome formation, autophagy, and phagocytosis in skin.\",\n      \"method\": \"Human genetics (6 nonsense/frameshift mutations in 9 individuals), immunofluorescence of skin biopsies, histopathology\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — human loss-of-function genetics with defined histopathological phenotype, multiple independent mutations\",\n      \"pmids\": [\"29336782\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Cell surface GPNMB on dormant breast cancer cells induces stem cell-like properties; wild-type GPNMB, but not a mutant lacking tumorigenic activity (YF mutant in hemITAM of cytoplasmic tail), induced CSC-like properties in breast epithelial cells and 3D sphere formation, demonstrating that the hemITAM tyrosine in the intracellular domain is required for GPNMB's tumorigenic function.\",\n      \"method\": \"3D sphere culture, cell surface protein isolation/flow cytometry, wild-type vs. YF-mutant GPNMB overexpression, sphere-forming frequency assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — structure-function mutagenesis identifying critical intracellular domain; single lab\",\n      \"pmids\": [\"30224376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GPNMB is a direct transcriptional target of TFE3 fusion oncoproteins in translocation renal cell carcinoma; GPNMB was upregulated in a PRCC-TFE3 transgenic mouse kidney tumor model and confirmed as a direct TFE3 transcriptional target; GPNMB was also upregulated following TSC2 loss in a MiT/TFE- and mTORC1-dependent fashion in renal cell lines.\",\n      \"method\": \"PRCC-TFE3 transgenic mouse model, CRISPR-Cas9 TSC2/TFE3/TFEB knockout cell lines, IHC, transcriptional target validation\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct transcriptional target validation in transgenic model and CRISPR-edited cell lines\",\n      \"pmids\": [\"31043488\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Hepatic Gpnmb is transcriptionally upregulated when the sterol regulatory element-binding protein (SREBP) pathway is inhibited in the liver; Gpnmb is processed to a secreted form that acts as a liver-WAT cross-talk factor, stimulating lipogenesis in white adipose tissue; Gpnmb inhibition (neutralizing antibody or liver-specific knockdown) improved metabolic parameters and promoted WAT beiging.\",\n      \"method\": \"Liver-specific Gpnmb knockdown, neutralizing antibody, secreted form identification, metabolic phenotyping in diet-induced obesity model\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — organ-specific knockdown with mechanistic pathway identification, multiple genetic and pharmacological approaches\",\n      \"pmids\": [\"32694855\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The kringle-like domain (KLD) in the extracellular domain of GPNMB is essential for its tumorigenic potential: a GPNMB(ΔKLD) deletion mutant lacked sphere and tumor formation activity and lost cell migration-promoting activity, despite retaining normal subcellular localization, Src-induced tyrosine phosphorylation, and homo-oligomerization.\",\n      \"method\": \"Domain deletion mutagenesis, 3D sphere/tumor formation assay, migration assay, subcellular localization, Western blotting\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — domain mutagenesis with functional validation; single lab\",\n      \"pmids\": [\"31127873\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Host GPNMB interacts with porcine circovirus type 2 (PCV2) ORF5 protein (demonstrated by GST pull-down, Co-IP, and confocal microscopy) and restricts PCV2 replication; GPNMB overexpression increased Cyclin A expression and reduced S phase, while knockdown had opposite effects, suggesting GPNMB modulates cell cycle to restrict viral replication.\",\n      \"method\": \"GST pull-down, Co-IP, confocal microscopy, lentiviral overexpression/knockdown, viral replication assays, cell cycle analysis\",\n      \"journal\": \"Frontiers in microbiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple binding assays (pulldown, Co-IP, confocal), functional replication assay; single lab\",\n      \"pmids\": [\"30671053\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Macrophage-derived soluble GPNMB activates tumor cells through the CD44 receptor to express cytokine IL-33 and its receptor IL-1RL1, triggering cancer stem cell sphere formation; recombinant IL-33 alone was sufficient to induce tumor spheroid formation with CSC features, establishing GPNMB→CD44→IL-33/IL-1RL1 paracrine axis.\",\n      \"method\": \"Gpnmb-mutant DBA/2J mouse tumor models, CD44 receptor blocking/use, recombinant IL-33 treatment, sphere formation assays\",\n      \"journal\": \"Cellular & molecular immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo mouse model, receptor identification with blocking, cytokine rescue; multiple orthogonal approaches\",\n      \"pmids\": [\"32728200\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"N-glycosylated GPNMB (specifically at Asn134) binds to the C-terminus of mutated EGFR and activates EGFR independently of its ligand, promoting phosphorylation at Y845 and activating downstream STAT3 signaling; mutation of N134 glycosylation abolished GPNMB-EGFR binding and inhibited downstream signaling and cancer metastasis in NSCLC.\",\n      \"method\": \"Membrane proteomics, Co-IP (GPNMB-EGFR binding), N134 glycosylation site mutagenesis, phosphorylation assays, metastasis models\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP identifying binding partner, glycosylation site mutagenesis with defined functional consequence, in vivo metastasis validation\",\n      \"pmids\": [\"33706413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GPNMB overexpression in an APP/PS1 Alzheimer's disease mouse model enhanced autophagy and reduced Aβ deposition via suppression of the mTOR signaling pathway; treatment with 3-MA (autophagy inhibitor) abolished the beneficial effect of GPNMB on Aβ clearance, placing GPNMB-mediated autophagy as the mechanistic route for Aβ clearance.\",\n      \"method\": \"Transgenic GPNMB overexpression in APP/PS1 mice, transmission electron microscopy for autophagy, immunofluorescence, Western blotting for mTOR/Beclin-1, pharmacological autophagy inhibition with 3-MA\",\n      \"journal\": \"Neuroscience letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic and pharmacological epistasis establishing mTOR→autophagy mechanism; single lab\",\n      \"pmids\": [\"34695452\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Gpnmb is a causal modifier of macrophage lysosome function: Gpnmb siRNA knockdown in AKR/J macrophages decreased lysosome function; CRISPR/Cas9 deletion of Gpnmb in RAW 264.7 macrophages similarly impaired lysosome function; the DBA/2J-Gpnmb+/SjJ substrain (with wild-type Gpnmb) showed recovered lysosome function compared to Gpnmb-nonsense DBA/2J, establishing Gpnmb as the causal gene at the Mlfm1 QTL.\",\n      \"method\": \"QTL mapping in AKR/J×DBA/2J intercross, siRNA knockdown, CRISPR/Cas9 knockout, lysosome function assay, congenic substrain comparison\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple independent genetic approaches (siRNA, CRISPR, QTL, congenic strain) converging on same phenotype\",\n      \"pmids\": [\"33986446\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Extracellular vesicles from GPNMB-overexpressing BMSCs activate Wnt/β-catenin signaling to stimulate osteogenic differentiation of BMSCs; DKK1 (Wnt/β-catenin inhibitor) blocked GPNMB-EV-induced osteogenesis, establishing Wnt/β-catenin as the downstream pathway.\",\n      \"method\": \"EV isolation from GPNMB-modified BMSCs, DKK1 inhibition of Wnt/β-catenin pathway, osteogenic differentiation assays, OVX rat model\",\n      \"journal\": \"Life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway epistasis via DKK1 inhibitor with in vivo validation; single lab\",\n      \"pmids\": [\"33582177\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GPNMB directly coimmunoprecipitates and co-localizes with α-synuclein (aSyn) in cells; in iPSC-derived neurons, loss of GPNMB resulted in loss of ability to internalize aSyn fibrils and develop aSyn pathology, linking GPNMB to aSyn fibril internalization as a mechanistic route to Parkinson's disease pathology.\",\n      \"method\": \"Co-immunoprecipitation, co-localization imaging, iPSC-derived neuron loss-of-function, aSyn fibril internalization assay\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP identifying aSyn as binding partner, loss-of-function in iPSC neurons with defined fibril internalization phenotype; high-profile journal with rigorous controls\",\n      \"pmids\": [\"35981040\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Macrophage-derived GPNMB activates aortic adventitial fibroblasts (AAFs) to produce extracellular matrix (ECM) via integrin αVβ1 receptor and downstream Akt and Erk signaling; Co-IP assay demonstrated GPNMB-integrin αVβ1 interaction, and siRNA or integrin inhibitor intervention confirmed this receptor mediates GPNMB's fibrotic effects on AAFs.\",\n      \"method\": \"Co-IP, siRNA knockdown, integrin inhibitor, Western blotting for Akt/Erk, in vitro AAF activation assays, GPNMB overexpression in macrophages\",\n      \"journal\": \"Translational research : the journal of laboratory and clinical medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP plus genetic/pharmacological epistasis; single lab\",\n      \"pmids\": [\"36566014\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Macrophage-derived GPNMB trapped by fibrotic ECM activates resident fibroblasts; the CD44/Serpinb2 pathway is activated in fibroblasts by GPNMB, promoting pulmonary fibrosis progression; GPNMB-neutralizing antibodies or macrophage deletion alleviated fibroblast activation in fibrotic ECM from silica-instilled mice.\",\n      \"method\": \"Fibrotic ECM fractionation/proteomics, GPNMB-neutralizing antibody, macrophage depletion, gene expression analysis (Serpinb2, CD44) in fibroblasts, silica-instilled mouse model\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — neutralizing antibody and macrophage depletion epistasis; pathway identification; single lab\",\n      \"pmids\": [\"36732560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CCN3 activates Wnt signaling (ligand-dependent or -independent) in TNBC, which increases MITF protein, which in turn transcriptionally induces GPNMB expression; GPNMB then activates the EGFR/MAPK pathway; CCN3 knockdown reduced GPNMB expression and EGFR activity, and GPNMB overexpression rescued the anti-cancer effects of CCN3 knockdown, establishing the CCN3→Wnt→MITF→GPNMB→EGFR/MAPK axis.\",\n      \"method\": \"siRNA knockdown, overexpression rescue, transcriptome profiling, Western blotting for pathway components, TCGA dataset validation\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — rescue experiment establishing epistasis; single lab\",\n      \"pmids\": [\"36737605\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GPNMB ameliorates neuroinflammation after subarachnoid hemorrhage via the AMPK/NFκB signaling pathway: recombinant GPNMB increased p-AMPK and suppressed p-NFκB and pro-inflammatory cytokines (IL-1β, IL-6, TNF-α); AMPK inhibitor (dorsomorphin) reversed the effects of rGPNMB on p-AMPK and p-NFκB, establishing AMPK as the downstream mediator.\",\n      \"method\": \"SAH mouse model, intracerebroventricular rGPNMB injection, AMPK inhibitor epistasis, Western blotting, ELISA, BBB integrity and behavior assays\",\n      \"journal\": \"Journal of neuroimmune pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological epistasis establishing AMPK→NFκB pathway; single lab\",\n      \"pmids\": [\"37919457\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Bone-marrow-derived macrophages are the primary source of GPNMB in injured hearts after myocardial infarction (established by lineage tracing and bone-marrow transplantation); GPNMB deficiency increases mortality and cardiac rupture while viral delivery of circulating GPNMB improves heart function; GPR39 was identified as a receptor for circulating GPNMB, and GPR39 absence negated the beneficial effects of GPNMB on cardiac repair.\",\n      \"method\": \"Lineage tracing, bone-marrow transplantation, genetic loss-of-function (GPNMB KO), viral GPNMB delivery, single-cell transcriptomics, GPR39 knockout mice\",\n      \"journal\": \"Nature cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic models (lineage trace, KO, viral delivery, GPR39 KO), receptor identification, in vivo validation\",\n      \"pmids\": [\"39455836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"GPNMB functions in microglial phagocytosis by wrapping engulfed pathogenic particles and presenting them to lysosomes through direct interaction with lysosomal vacuolar-type proton ATPase catalytic subunit A (ATP6V1A); genetic ablation of GPNMB impaired both phagocytic engulfment and degradation; activating ATP6V1A rescued GPNMB-deficiency-caused phagocytosis impairment.\",\n      \"method\": \"GPNMB genetic ablation, Co-immunoprecipitation (GPNMB-ATP6V1A interaction), phagocytosis assays (multiple substrates), ATP6V1A activation rescue, in vivo seizure/epilepsy model\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP identifying novel binding partner (ATP6V1A), genetic KO with phagocytosis phenotype, rescue by pathway activation, in vivo validation\",\n      \"pmids\": [\"39992792\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GPNMB is a type I transmembrane glycoprotein whose expression is transcriptionally driven by MITF downstream of mTORC1 and PI3K/Akt signaling; its ectodomain is shed by ADAM10 (regulated by PKC/Ca2+ signaling) to generate a bioactive secreted form that signals through CD44 (reducing inflammation and promoting MSC/fibroblast responses), integrin α5β1 (activating Src/FAK to drive cancer metastasis via its RGD motif), GPR39 (mediating cardiac repair), and mutated EGFR (via N134 glycosylation-dependent binding to activate STAT3); the intracellular hemITAM domain mediates tumorigenic and stem cell-promoting functions; in macrophages GPNMB acts as a negative feedback regulator of inflammation (translocating from Golgi to peripheral vesicles upon activation) and promotes M2 polarization via IL-4-STAT6, while in neurons and microglia it relocates to the nucleus during ER stress to enhance BiP pre-mRNA splicing, interacts with α-synuclein to mediate fibril internalization, and functions in lysosomal/phagocytic pathways through interaction with ATP6V1A.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"GPNMB is a type I transmembrane glycoprotein that functions as a multifunctional signaling ligand and lysosomal/melanosomal regulator, with roles spanning immune modulation, melanogenesis, neuroprotection, and cancer progression. Its ectodomain is shed by ADAM10 and acts in paracrine fashion through multiple receptors — CD44 on astrocytes, mesenchymal stem cells, and fibroblasts to suppress neuroinflammation and activate ERK/Akt signaling [PMID:29519253, PMID:26442636, PMID:36732560]; syndecan-4 on T cells to inhibit T-cell activation and promote tumor immune evasion [PMID:20570888, PMID:31822499]; integrin α5β1/αVβ1 to drive metastasis via Src/FAK [PMID:25772243, PMID:36566014]; and GPR39 to mediate cardioprotection after myocardial infarction [PMID:39455836]. Transcriptionally regulated by MITF/TFE3 family members downstream of the mTORC1–GSK3β axis [PMID:18313864, PMID:24789918, PMID:31043488], GPNMB promotes lysosomal function and autophagosome–lysosome fusion through interaction with ATP6V1A, is essential for melanosome biogenesis, and under ER stress translocates to the nucleus to enhance BiP pre-mRNA splicing independently of canonical UPR sensors [PMID:33986446, PMID:39992792, PMID:22912767, PMID:28939899]. Loss-of-function mutations in GPNMB cause autosomal-recessive amyloidosis cutis dyschromica in humans [PMID:29336782].\",\n  \"teleology\": [\n    {\n      \"year\": 2007,\n      \"claim\": \"Establishing GPNMB as an anti-inflammatory regulator in macrophages resolved the question of whether this melanocyte-associated glycoprotein had immune function, revealing that it suppresses LPS-induced pro-inflammatory mediators and redistributes from Golgi to peripheral vesicles upon activation.\",\n      \"evidence\": \"Overexpression in RAW264.7 macrophages plus DBA loss-of-function mouse validation with cytokine ELISA and immunofluorescence\",\n      \"pmids\": [\"17475886\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor mediating macrophage anti-inflammatory effect unknown\", \"Signaling pathway downstream of GPNMB in macrophages uncharacterized\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identification of MITF as the direct transcriptional regulator of GPNMB via conserved M-box elements established the gene's position in the melanocyte transcription factor hierarchy and explained its co-regulation with pigmentation genes.\",\n      \"evidence\": \"EMSA with supershift, luciferase reporter with site-directed mutagenesis, in vivo enhancer transgenic assays in melanoblasts\",\n      \"pmids\": [\"18313864\", \"18983539\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other MiT/TFE family members regulate GPNMB in non-melanocyte lineages was untested\", \"Post-transcriptional regulation unexplored\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Two critical receptor–ligand pairs were defined: ADAM10 was identified as the sheddase releasing the GPNMB ectodomain, and syndecan-4 was identified as the T-cell receptor through which tumor-expressed GPNMB inhibits anti-tumor immunity, establishing GPNMB as an immune checkpoint molecule.\",\n      \"evidence\": \"siRNA knockdown of candidate sheddases in breast cancer cells; syngeneic tumor growth in immunocompetent vs. immunodeficient mice with SD-4 blocking antibody\",\n      \"pmids\": [\"20711474\", \"20570888\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ADAM10 shedding is regulated by specific stimuli was unknown\", \"Whether SD-4 interaction mediates immunosuppression beyond melanoma was untested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"GPNMB was shown to be essential for melanosome biogenesis independently of MITF transcriptional regulation, demonstrating a direct structural/organizational role within the melanocyte organelle system.\",\n      \"evidence\": \"siRNA knockdown in PIG1 melanocytes with TEM quantification of melanosomes and immunoblot for melanosome cargo proteins\",\n      \"pmids\": [\"22912767\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of melanosome assembly promotion unknown\", \"Whether GPNMB acts as a structural scaffold or signaling component within melanosomes was unresolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Placing GPNMB downstream of the mTORC1–MITF axis in macrophages under lysosomal stress explained why GPNMB is induced in metabolically stressed tissues and connected its anti-inflammatory function to nutrient sensing.\",\n      \"evidence\": \"Multiple lysosomal stressors (palmitate, chloroquine, rapamycin), MITF shRNA epistasis in RAW264.7 and adipose tissue macrophages\",\n      \"pmids\": [\"24789918\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether GPNMB itself feeds back to modulate mTORC1 was unknown\", \"Identity of GPNMB's receptor in the macrophage autocrine circuit unresolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Dissection of GPNMB's pro-metastatic mechanism revealed that its RGD motif binds integrin α5β1 to activate Src/FAK and that the cytoplasmic tail (via hemITAM) drives primary tumor growth through NRP-1/VEGF signaling, separating tumorigenic from metastatic functions.\",\n      \"evidence\": \"RGD and cytoplasmic tail domain mutants, integrin Co-IP, NRP-1 siRNA, orthotopic breast cancer and metastasis models\",\n      \"pmids\": [\"25772243\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise structural basis of RGD–integrin interaction unresolved\", \"Whether hemITAM phosphorylation is required for NRP-1 upregulation was untested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"The discovery that GPNMB translocates to the nucleus under ER stress and promotes BiP pre-mRNA splicing independently of IRE1/PERK/ATF6 revealed an unexpected non-canonical role in the unfolded protein response and neuroprotection.\",\n      \"evidence\": \"Nuclear fractionation, BiP pre-mRNA splicing assay after thapsigargin, GPNMB transgenic mice with reduced MCAO infarcts\",\n      \"pmids\": [\"28939899\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which GPNMB promotes splicing (direct RNA binding vs. co-factor recruitment) unknown\", \"Whether nuclear GPNMB function extends beyond BiP untested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"CD44 was validated as a GPNMB receptor on astrocytes mediating anti-neuroinflammatory effects, and separately, human loss-of-function mutations in GPNMB were shown to cause amyloidosis cutis dyschromica, establishing the first Mendelian disease link.\",\n      \"evidence\": \"Recombinant GPNMB on CD44-KO primary astrocytes; compound heterozygous/homozygous truncating GPNMB alleles in affected families with skin biopsies and EM\",\n      \"pmids\": [\"29519253\", \"29336782\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CD44 downstream signaling cascade in astrocytes incompletely defined\", \"Whether amyloid deposition results from loss of melanocyte GPNMB specifically or from broader epidermal dysfunction was unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Multiple discoveries expanded the GPNMB regulatory and effector network: TFE3 fusions and TSC2 loss upregulated GPNMB through MiT/TFE–mTORC1 axis; liver-secreted GPNMB was shown to drive adipose lipogenesis and obesity; and host DC-HIL/GPNMB was established as a resistance factor to anti-PD-L1 immunotherapy.\",\n      \"evidence\": \"CRISPR KO of TSC2/TFE3/TFEB in cell lines plus transgenic mice; liver-specific knockdown and neutralizing antibody in diet-induced obesity; genetic DC-HIL host deletion converting anti-PD-L1-resistant tumors to responsive\",\n      \"pmids\": [\"31043488\", \"32694855\", \"31822499\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether metabolic GPNMB signals through CD44 or a distinct receptor on adipocytes unknown\", \"Whether combining anti-GPNMB with anti-PD-L1 is sufficient for durable anti-tumor immunity untested in genetic models\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"GPNMB was causally linked to lysosome function through QTL mapping and genetic validation: it recruits LC3 to autophagosomes for lysosome fusion, and the DBA/2J natural Gpnmb nonsense variant explains the strain's lysosomal defect, unifying its lysosomal biology with its autophagy-promoting effects.\",\n      \"evidence\": \"QTL mapping, siRNA and CRISPR-Cas9 KO in macrophages, lysosome function assay with dual-labeled indicator, DBA/2J-Gpnmb+/SjJ rescue\",\n      \"pmids\": [\"33986446\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether GPNMB directly binds LC3 or acts through an adaptor unknown\", \"Structural basis for GPNMB's role at the autophagosome–lysosome interface unresolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"GPNMB was identified as a physical interactor and functional receptor for α-synuclein fibrils, required for their internalization in neurons, directly implicating GPNMB in synucleinopathy pathogenesis.\",\n      \"evidence\": \"Co-IP and colocalization, iPSC-derived neuron GPNMB loss-of-function with impaired fibril internalization\",\n      \"pmids\": [\"35981040\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether GPNMB mediates fibril clearance (protective) or seeding (pathogenic) in vivo is context-dependent and incompletely resolved\", \"Binding interface between GPNMB and α-synuclein fibrils uncharacterized\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"GPR39 was identified as a receptor for circulating GPNMB mediating cardioprotection after myocardial infarction, with bone-marrow-derived macrophages as the primary source, extending the receptor repertoire beyond CD44, SD-4, and integrins.\",\n      \"evidence\": \"Lineage tracing, bone marrow transplantation, GPNMB genetic loss-of-function, viral rescue, GPR39 KO mice with cardiac functional readouts\",\n      \"pmids\": [\"39455836\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling of GPR39 upon GPNMB binding undefined\", \"Whether GPR39 mediates GPNMB effects in non-cardiac tissues unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"The molecular basis of GPNMB's lysosomal function was refined by identification of ATP6V1A as a direct interaction partner: GPNMB wraps engulfed particles and presents them to lysosomes, and ATP6V1A activation rescues phagocytic impairment caused by GPNMB deficiency.\",\n      \"evidence\": \"Co-IP of GPNMB–ATP6V1A, genetic ablation, live imaging of phagocytosis, ATP6V1A activator rescue in microglia\",\n      \"pmids\": [\"39992792\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether GPNMB–ATP6V1A interaction is direct or mediated by an adaptor complex unknown\", \"Structural details of GPNMB wrapping mechanism unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key open questions include: the structural basis for GPNMB's multi-receptor engagement, whether nuclear GPNMB directly binds RNA or recruits splicing factors, and how tissue-specific receptor usage (CD44 vs. SD-4 vs. GPR39 vs. integrins) is determined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal or cryo-EM structure of GPNMB ectodomain or its receptor complexes\", \"Mechanism of nuclear import and RNA-related activity undefined\", \"Tissue-specific receptor selection logic unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [2, 6, 11, 12, 13, 26, 27, 33]},\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [7, 26]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [34]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 6, 30, 31]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 6, 7, 36]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [24, 34]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [21]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [1, 13, 33]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [0, 16]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 2, 6, 30, 31]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [24, 28, 34]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 11, 19, 29, 33]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [6, 7, 29, 30]},\n      {\"term_id\": \"R-HSA-1852241\", \"supporting_discovery_ids\": [16, 24, 34]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [4, 5, 8, 10, 22]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CD44\",\n      \"SDC4\",\n      \"ADAM10\",\n      \"MITF\",\n      \"ATP6V1A\",\n      \"GPR39\",\n      \"ITGA5\",\n      \"EGFR\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"GPNMB is a heavily glycosylated type I transmembrane protein that functions as a multifunctional regulator of inflammation, melanosome biogenesis, lysosomal activity, and tissue repair, with context-dependent roles in cancer progression and neurodegeneration. Transcriptionally controlled by MITF and related MiT/TFE family members downstream of mTORC1 and PI3K/Akt signaling [PMID:18313864, PMID:24789918, PMID:25889792, PMID:31043488], GPNMB undergoes ADAM10-mediated ectodomain shedding regulated by PKC/Ca²⁺ to generate a soluble form that signals through CD44 (suppressing inflammation in macrophages and astrocytes and activating mesenchymal stromal cells), integrin α5β1/αVβ1 (driving Src/FAK-dependent cancer metastasis via its RGD motif), GPR39 (mediating cardiac repair after myocardial infarction), and glycosylation-dependent binding to mutant EGFR (activating STAT3 in NSCLC) [PMID:20711474, PMID:29519253, PMID:25772243, PMID:39455836, PMID:33706413]. Intracellularly, GPNMB is essential for melanosome formation, promotes microglial phagocytosis by wrapping engulfed particles and delivering them to lysosomes through direct interaction with ATP6V1A, mediates α-synuclein fibril internalization in neurons, and relocates to the nucleus under ER stress to enhance BiP pre-mRNA splicing independently of canonical UPR transducers [PMID:22912767, PMID:39992792, PMID:35981040, PMID:28939899]. Loss-of-function mutations in GPNMB cause autosomal-recessive amyloidosis cutis dyschromica in humans, characterized by dermal amyloid deposits, melanocyte loss, and macrophage infiltration [PMID:29336782].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"The initial identification of GPNMB as a transmembrane glycoprotein enriched in low-metastatic melanoma cells, whose partial overexpression reduced metastatic potential, established the gene as a candidate suppressor of melanoma aggressiveness and linked it to pigmentation biology.\",\n      \"evidence\": \"Subtractive cDNA library from melanoma cell lines with in vivo xenograft validation\",\n      \"pmids\": [\"7814155\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of metastasis suppression unknown\", \"Partial cDNA used; full-length function not tested\", \"Single xenograft model\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstration that GPNMB negatively regulates macrophage inflammatory responses — translocating from Golgi to peripheral vesicles upon activation — and that its natural loss-of-function (DBA/2J mice) elevates proinflammatory cytokines, established GPNMB as an intrinsic brake on innate immune activation.\",\n      \"evidence\": \"Overexpression in RAW264.7 macrophages, Golgi co-localization imaging, cytokine ELISA, DBA/2J Gpnmb-mutant mouse\",\n      \"pmids\": [\"17475886\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor mediating anti-inflammatory effect not yet identified\", \"Mechanism of vesicular translocation not resolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identification of MITF as the direct transcriptional regulator of GPNMB — binding a conserved M-box in the promoter and an enhancer element active in melanoblasts — placed GPNMB within the MiT/TFE transcriptional network governing melanocyte and osteoclast differentiation.\",\n      \"evidence\": \"EMSA, promoter mutagenesis/reporter assay, transgenic enhancer analysis, Mitf-mutant mice\",\n      \"pmids\": [\"18313864\", \"18983539\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether additional MiT family members (TFE3/TFEB) regulate GPNMB in non-melanocyte contexts was unknown\", \"Upstream signals controlling MITF occupancy at the GPNMB locus not resolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identification of ADAM10 as the sheddase releasing GPNMB's bioactive ectodomain, regulated by PKC/Ca²⁺ signaling, and the finding that GPNMB on tumor cells inhibits T cell activation via syndecan-4, established two key functional modes: paracrine signaling through ectodomain shedding and immune checkpoint activity on cancer cells.\",\n      \"evidence\": \"siRNA screen of sheddases in breast cancer cells; GPNMB knockdown in B16F10 melanoma with in vivo growth in immunocompetent vs. immunodeficient mice; syndecan-4 blocking\",\n      \"pmids\": [\"20711474\", \"20056711\", \"20570888\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ADAM10 is the sole sheddase in all cell types not established\", \"Structural basis of syndecan-4 interaction unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstrating that GPNMB silencing sharply reduced melanosome number and melanosomal protein expression (tyrosinase, Trp1, Pmel17) in an MITF-independent manner revealed a direct structural or regulatory role for GPNMB in organelle biogenesis beyond transcriptional control.\",\n      \"evidence\": \"siRNA knockdown in melanocytes, transmission electron microscopy for melanosome counting, Western blotting\",\n      \"pmids\": [\"22912767\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which GPNMB maintains melanosomal proteins is not defined\", \"Whether GPNMB acts in melanosome maturation vs. biogenesis not distinguished\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Placing GPNMB downstream of mTORC1 inhibition → MITF nuclear translocation in macrophages during lysosomal stress connected GPNMB induction to the cellular stress-sensing apparatus and explained its upregulation in obese adipose tissue macrophages.\",\n      \"evidence\": \"shRNA MITF knockdown, mTORC1 inhibition with Torin1/palmitate, nuclear MITF imaging, in vivo obese mouse adipose tissue macrophage isolation\",\n      \"pmids\": [\"24789918\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether mTORC1-independent signals also regulate GPNMB in macrophages not resolved\", \"Direct lysosomal stress sensor upstream of mTORC1 not identified\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Structure–function dissection showed that GPNMB's RGD motif mediates integrin α5β1 binding to activate Src/FAK signaling for lung metastasis, while both RGD and the cytoplasmic tail are required for primary tumor growth; separately, PI3K/Akt inhibition→GSK3β→MITF was identified as an alternative pathway activating GPNMB transcription in dendritic cells.\",\n      \"evidence\": \"RGD motif mutagenesis, Co-IP of integrin complex, Src/FAK signaling assays, in vivo metastasis model; pharmacological epistasis in dendritic cells\",\n      \"pmids\": [\"25772243\", \"25889792\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether integrin binding and syndecan-4 binding are independent or cooperative not resolved\", \"Role of cytoplasmic tail hemITAM in integrin-mediated signaling not dissected\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Discovery that GPNMB relocates to the nucleus during ER stress to promote BiP pre-mRNA splicing — independently of IRE1, PERK, and ATF6 — revealed an unexpected non-canonical function as a nuclear RNA-processing factor in the stress response.\",\n      \"evidence\": \"Thapsigargin-induced ER stress, nuclear fractionation, mRNA splicing analysis, pathway inhibitor exclusion, GPNMB transgenic mouse MCAO model\",\n      \"pmids\": [\"28939899\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of nuclear import unknown\", \"RNA-binding or spliceosome interaction partners not identified\", \"Not independently replicated\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Genetic proof from CD44-knockout astrocytes that GPNMB's anti-inflammatory signaling requires CD44, and human genetic evidence that GPNMB loss-of-function truncating mutations cause autosomal-recessive amyloidosis cutis dyschromica, together validated CD44 as a bona fide GPNMB receptor and established GPNMB's non-redundant physiological role in skin homeostasis.\",\n      \"evidence\": \"CD44-KO primary astrocyte assays with recombinant GPNMB; six independent GPNMB truncating alleles in nine ACD patients with histopathological characterization\",\n      \"pmids\": [\"29519253\", \"29336782\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CD44 mediates GPNMB signaling in all anti-inflammatory contexts not established\", \"Molecular link between GPNMB loss and amyloid deposition not mechanistically defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identification of TFE3 fusion oncoproteins as direct transcriptional activators of GPNMB (paralleling MITF), and demonstration that the kringle-like domain (KLD) in the ectodomain is essential for tumorigenic sphere formation, refined both the transcriptional regulation and the domain architecture required for GPNMB's oncogenic functions.\",\n      \"evidence\": \"PRCC-TFE3 transgenic mouse, CRISPR TSC2/TFE3/TFEB KO cell lines; KLD deletion mutagenesis with sphere/tumor assays\",\n      \"pmids\": [\"31043488\", \"31127873\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"KLD binding partner not identified\", \"Whether TFE3 and MITF bind the same or distinct GPNMB regulatory elements not resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Convergent genetic approaches (siRNA, CRISPR KO, QTL mapping, congenic strains) established GPNMB as a causal modifier of macrophage lysosome function and the gene underlying the Mlfm1 QTL, directly linking GPNMB to lysosomal competence beyond transcriptional correlation.\",\n      \"evidence\": \"AKR/J×DBA/2J intercross QTL, CRISPR Gpnmb KO in RAW264.7, siRNA, DBA/2J-Gpnmb+/SjJ congenic comparison\",\n      \"pmids\": [\"33986446\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism by which GPNMB enhances lysosome function not identified at this stage\", \"Whether GPNMB acts on lysosome biogenesis vs. acidification vs. substrate delivery unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Co-immunoprecipitation of GPNMB with α-synuclein and the finding that GPNMB loss in iPSC-derived neurons abolishes α-synuclein fibril internalization established GPNMB as a receptor/co-receptor for pathological α-synuclein uptake, directly implicating it in Parkinson's disease pathogenesis.\",\n      \"evidence\": \"Co-IP, co-localization, iPSC-derived neuron GPNMB loss-of-function, α-synuclein fibril internalization assay\",\n      \"pmids\": [\"35981040\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether GPNMB-mediated fibril internalization is protective or pathogenic in vivo not resolved\", \"Co-receptor or downstream signaling upon fibril binding not identified\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identification of GPR39 as a receptor for circulating GPNMB — with GPR39 knockout negating GPNMB's cardioprotective effects after myocardial infarction — added a new receptor-signaling axis and demonstrated that bone-marrow-derived macrophages are the primary source of GPNMB in injured hearts.\",\n      \"evidence\": \"Lineage tracing, bone-marrow transplantation, GPNMB KO, viral GPNMB delivery, GPR39 KO mice, single-cell transcriptomics\",\n      \"pmids\": [\"39455836\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"GPR39 downstream signaling pathway in cardiomyocytes not fully characterized\", \"Whether GPR39 mediates GPNMB signaling in non-cardiac tissues not known\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"The discovery that GPNMB wraps phagocytosed particles and delivers them to lysosomes via direct interaction with the V-ATPase subunit ATP6V1A — with ATP6V1A activation rescuing GPNMB-deficiency phenotypes — provided the first mechanistic link between GPNMB's lysosomal and phagocytic functions.\",\n      \"evidence\": \"Co-IP of GPNMB–ATP6V1A, GPNMB genetic ablation, multi-substrate phagocytosis assays, ATP6V1A activation rescue, in vivo seizure model\",\n      \"pmids\": [\"39992792\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of GPNMB–ATP6V1A interaction not resolved\", \"Whether this mechanism operates in non-microglial phagocytes not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: how GPNMB's multiple receptor interactions (CD44, integrins, GPR39, EGFR, syndecan-4) are coordinated across tissues; the structural basis and functional consequences of GPNMB's nuclear translocation and RNA-splicing activity; and whether GPNMB-mediated α-synuclein fibril internalization is net protective or pathogenic in neurodegeneration in vivo.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of full-length GPNMB or its receptor complexes\", \"In vivo consequence of GPNMB-mediated α-synuclein uptake for disease progression unknown\", \"Nuclear RNA-processing mechanism not independently replicated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [6, 15, 39]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [5, 18, 26, 33, 43]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 25, 36, 44]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [6, 15, 22, 28]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [1, 7]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [3, 36, 44]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [1, 7]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [5, 9, 18, 30, 43]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [24]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 6, 25, 26, 42]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [15, 18, 19, 34, 41, 43]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [35, 36]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [2, 22, 34]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [8, 10, 11]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"MITF\", \"ADAM10\", \"CD44\", \"ATP6V1A\", \"GPR39\", \"SNCA\", \"ITGA5\"],\n    \"other_free_text\": []\n  }\n}\n```"}